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Over the past decade, molecular imaging has emerged as a powerful 
tool to visualize biological processes of living subjects on the cellular or 
molecular level. Such techniques greatly improve our understanding of 
disease and drug activity. Since molecular imaging relies on exoteric imaging 
agents as reporters to send detectable signals towards the outside, 
investigation of the imaging agents is of vital importance. However, the 
quantification of the imaging agents is still one of the challenges facing this 
work.  
Magnetic resonance (MR) imaging has been widely used as one of the 
imaging modalities for molecular imaging. This dissertation focuses on the 
quantification of the gadolinium based contrast agent (GBCA) and the 19F 
contained drug and imaging agent used in MR imaging and spectroscopy. MR 
imaging pulse sequence, hardware and novel imaging agents have been 
developed to achieve more rapid and accurate quantitative methodologies for 
determination of imaging agents. 
In the first part of the dissertation, a rapid T1 and T2 mapping 
technique ms-DSEPI-T12 is introduced to assess in vivo dynamic T1 profile. 




experiments with voxel size of 1.0×1.0×2.0 mm3. Comparing the conventional 
T1 mapping methods, e.g., inversion recovery, which takes several to tens of 
minutes, ms-DSEPI-T12 can provide much higher temporal resolution. 
In the second part, 19F MR spectroscopy has been collected to monitor 
an ocular corticosteroid, TAP, with total dosage of 9 µmol using a rabbit 
model. Intravitreal and subconjunctival injections were used to deliver TAP 
into the rabbit eyes. The elimination half-lives of TAP in vivo and in 
postmortem rabbit eyes are 7.8±1.1, 17.2±2.1 Hr using intravitreal injection, 
and 0.5±0.1, 6.0±1.5 Hr using subconjunctival injection, which are used to 
investigate the possible ocular elimination pathway of TAP. 
In the last part, 19F MR imaging using a newly developed 19F MR 
imaging agent, 19FIT, was done on a 3T clinical system. For the mice 
experiment, conducted with voxel size 1.5×1.5×3.0 mm3 and 5 min 9 sec 
imaging time, relatively high SNR (ranges from 10 to 60 in heart, liver and 
bladder) of the 19F imaging is achieved. 
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MAGNETIC RESONANCE IMAGING IN MOLECULAR 
IMAGING AND DRUG DELIVERY RESEARCH 
1.1 Introduction 
For conventional noninvasive medical imaging methods, such as 
magnetic resonance imaging (MRI) and computed tomography (CT), the 
imaging contrast is mainly from physical properties or the physiology of 
tissues. For example, the contrasts in most MR images are based on spin 
density, T1 (spin-lattice relaxation time), T2 (spin-spin relaxation time), and 
diffusivity of the hydrogen nuclei in the water molecules; CT images are 
based on the absorption or scattering of incident X-ray in tissue. The contrast 
sources determine that those imaging methods are mainly focused on 
detection of diseases on a macroscopic level, such as anatomical changes of 
the tissues.  
With the rapid advances in molecular and cellular biology, 
understanding of the disease mechanism at the molecular or genetic level has 
been established. The molecular or genetic changes, which precede 
manifestation of disease, are the theoretical basis of early detection and 
diagnosis of the disease. The revealing of molecular pathways of the 
 
underlying disease can lead to new treatment and therapy on the molecular 
level. Therefore, visualization and quantification of molecular biologic 
processes may be beneficial to molecular biology research, early clinical 
diagnosis, new therapy development and novel drug delivery investigation 
and evaluation. The demand has created a boom in molecular imaging. 
MRI, as one of the major imaging modalities, has been increasingly 
used in molecular imaging approaches, because of its high spatial resolution 
and combination of anatomical and functional imaging. The basic theory of 
MRI is introduced in Chapter 2. 
Using MRI to characterize specific biologic processes, a variety of 
imaging agents have been involved. Upon the introduction of the drug carrier 
molecules, such as the gadolinium-based contrast agent (GBCA) and the 19F 
imaging agent, quantification of the concentration is the first step for further 
evaluation of the pharmacokinetics. Here, a brief review is introduced of 
paramagnetic T1 contrast agent for 1H imaging and fluorine compounds for 
19F imaging. 
1.2 1H MRI Using Paramagnetic T1 Contrast Agents 
The mechanism of tracing paramagnetic T1 contrast agents is based on 
the fact that the paramagnetic ion can shorten the proton T1 relaxation time 
of the large pool of mobile water molecules existing in the human body. The 
relationships between the concentration of contrast agent, T1 relaxation time 
and 1H signal are described by equations 1.1 and 1.2. Here, C is the 
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concentration of contrast agent, R1 a constant called T1 relaxavity, T10 the T1 
value in the absence of contrast agent, S the 1H signal intensity, S0 the signal 
intensity from the fully recovered magnetization in thermal equilibrium, and 
TR the recovery time. Equation 1.2 only shows the simplest relationship 








ሻ     . . . . ሺ1.1ሻ 





೅మ     . . . . ሺ1.2ሻ 
Therefore, to trace and quantify paramagnetic contrast agents, it is 
necessary to measure precontrast and postcontrast images and T1. However, 
it takes at least a few to tens of minutes to measure the T1 using conventional 
imaging methods. Due to the lack of rapid T1 measurement techniques, in 
practical pharmacokinetic studies, T1 and T2 are measured only on solution 
phantoms and used to estimate the concentration of GBCA. By doing so, 
several factors greatly affect the accuracy of the quantification, such as the 
nonlinear relationship between the 1H signal and the contrast agent 
concentration, the intrinsic contrast sources in tissues and the dependence of 
imaging sequence and parameters.  
In Chapter 3, a rapid T1 measurement technique is introduced to 
address the problem. 
3
1.3 19F MRI Using Fluorine Compounds 
Besides paramagnetic T1 contrast agents, fluorinated compounds are 
another family of MR imaging agents, which have been attempted for 19F 
MRI in the past decade.  
Heteronuclear MR imaging or spectroscopy has an advantage over the 
indirect monitoring of paramagnetic-ion based 1H MRI because heteronuclear 
imaging allows direct detection and quantification of the imaging agent. 
NMR properties of several nuclei commonly used in MRI are listed in Table 
1.1.  Among the nuclei used in heteronuclear imaging, 19F has several 
advantages over others, which include (1) the second highest gyromagnetic 
ratio after 1H, which leads to relatively high sensitivity, (2) no detectable 
background 19F MR signal from biological tissues, and (3) 100% natural 
abundance. 
In Chapter 4, an application of 19F MR spectroscopy is demonstrated to 
investigate the ocular pharmacokinetics of corticosteroids that contain a 
fluorine atom. Despite the strength, the low signal intensity is the biggest 
obstacle for application of 19F MR. Therefore, the research on the MR side 
was focused on MR hardware improvement for 19F MRI. 
Chapter 5 presents a 19F MRI pharmacokinetic study using a newly 
developed 19F imaging agent, which overcomes several major problems in 19F 
MRI using perfluorocarbon (PFC), such as low signal intensity, complex peak 
shapes, long T1 and long in vivo retention time. Pharmacokinetic properties 
4
and possible applications in drug delivery research of 19F imaging agent have 
been investigated and discussed. 
 
 
Table 1.1 NMR properties of nuclei commonly used in MRI. 
Nuclei Spin Gyromagnetic Ratio 





1H 1/2 26.752 99.985 1.00 
13C 1/2 6.728 1.108 1.76×10-4 
19F 1/2 25.181 100.00 0.834 
23Na 3/2 7.080 100.00 9.27×10-2 
31P 1/2 10.841 100.00 6.65×10-2 





BASIC THEORY OF MAGNETIC RESONANCE 
IMAGING 
Magnetic resonance imaging (MRI) utilizes the property of nuclear 
magnetic resonance to image nuclei of atoms inside the body. In this chapter, 
the basic theory of magnetic resonance imaging is introduced; more detail can 
be found in (1-4). 
2.1 Single Spin in External Magnetic Field - Classical 
Description 
If we consider a nucleus as a spinning ball with uniform charge 
distribution on the surface, due to the movement of the charge, the nucleus 
possesses a magnetic moment ߤሬറ. In the presence of an external magnetic field 
ܤሬሬറ, the nucleus will experience a torque ߤሬറൈܤሬሬറ. From classical mechanics, the 
torque equals the rate of the change of the angular momentum ܬറ 
݀ ܬറ
݀ݐ
 ൌ ߤሬറ ൈ ܤሬሬറ     . . . . ሺ2.1ሻ 
 
Since the angular momentum of the nucleus is related to the magnetic 
moment by ߤሬറൌ ߛ ܬറ, where ߛ is the gyromagnetic ratio and its value varies 
between different nuclei, equation 2.1 can be rewritten as  
݀ ߤሬറ
݀ݐ
 ൌ ߤሬറ ൈ  ߛ ܤሬሬറ     . . . . ሺ2.2ሻ 
Assuming ܤሬሬറ is along the positive z direction, i.e. ܤሬሬറൌ ܤ଴̂ݖ , equation 2.2 can be 















      . . . . ሺ2.3ሻ 















      . . . . ሺ2.4ሻ 
where ߱଴ ൌ  ߛܤ଴. 
Solving the differential equation 2.4, we get 
ቐ
ߤ௫ሺݐሻ ൌ  ߤ௫ሺ0ሻ cosሺ߱଴ݐሻ ൅ ߤ௬ሺ0ሻ sinሺ߱଴ݐሻ
ߤ௬ሺݐሻ ൌ  െߤ௫ሺ0ሻ sinሺ߱଴ݐሻ ൅ ߤ௬ሺ0ሻ cosሺ߱଴ݐሻ
ߤ௭ሺݐሻ ൌ  ߤ௭ሺ0ሻ
      . . . . ሺ2.5ሻ 
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The results show that the x and y components of ߤሬറ rotate about the z-axis, 
which ܤሬሬറ lies on, with angular frequency ߱଴ ൌ  ߛܤ଴, and the z component of ߤሬറ 
stays unchanged, which means the vector ߤሬറ  rotates about vector ܤሬሬറ  with 
angular velocity  of  ሬ߱ሬሬറ ൌ െߛ ܤሬሬറ, as shown in Fig. 2.1. 
2.2 Single Spin in External Magnetic Field - Quantum 
Description 
All nuclei have a spin quantum number of either half integer or integer. 
The spin quantum number ܫറ  relates to the angular momentum ܬറ  by the 
equation 2.6: 
ܬറൌ ԰ ܫറ     . . . . ሺ2.6ሻ 
The interaction energy of the nuclei with the external magnetic field ܤሬሬറൌ ܤ଴̂ݖ, 
which is called the Zeeman interaction, is given by  
Figure 2.1 The motion of a single spin magnetic moment in an
external magnetic field. 
8
ܧ ൌ െߤറ ·ܤሬሬറൌ െߤ௭ܤ଴ ൌ െߛܬ௭ܤ଴ ൌ െߛ԰ܫ௭ܤ଴     . . . . ሺ2.7ሻ 
Therefore, a nucleus with a spin quantum number other than 0 will have 
ܧ ൌ െߛ԰ܤ଴݉, with m as the eigenvalue of ܫ௭,  ݉ ൌ െܫ,െܫ ൅ 1,ڮ , ܫ െ 1, ܫ. If we 
use |݉ۄ to represent different eigenstates of Iz, the time evolution of these 
eigenstates would be exp ሺെ ௜ா೘௧
԰
ሻ|݉ۄ. If the initial state is  
߰ሺ0ሻ ൌ ෍ ܿ௠
ூ
௠ୀିூ
|݉ۄ     . . . . ሺ2.8ሻ 
at a later time t,  






ሻ|݉ۄ     . . . . ሺ2.9ሻ 
then the expectation value of the components of ߤറ  at an arbitrary time t 
would be  







൫ܧ௠′ െ ܧ௠൯ሿ     . . . . ሺ2.10ሻ 
where n represents x, y or z.  
Take ܫ ൌ ଵ
ଶ
 as an example, we have ݉ ൌ േଵ
ଶ
,  




ฬ cosሺߙ െ ߚ ൅ ߛܤ଴ݐሻ 
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ሻ/2     . . . . ሺ2.11ሻ 





From the equations 2.11, we note that ۃߤ௭ሺݐሻۄ is independent of time, 
and ۃߤ௫ሺݐሻۄ  and ۃߤ௬ሺݐሻۄ  oscillate with frequency ߛܤ଴  while ۃߤ௫ሺݐሻۄଶ ൅ ۃߤ௬ሺݐሻۄଶ 
remains constant. These show that ۃߤറۄ is rotating about the z axis at a fixed 
angle from the z axis, which is exactly the rotation shown in the classical 
description. 
2.3 Bulk Magnetization 
In a bulk material containing a large amount of spins, a magnetization 





      . . . . ሺ2.12ሻ 
Here ܰ indicates the total number of the spins. 
In the absence of an external magnetic field, the orientation of the 
nuclear spins in the bulk material is random. Therefore ܯሬሬሬറ is zero; when the 
material is placed in a magnetic field ܤ଴̂ݖ, using spin 
ଵ
ଶ
 as an example, the 
nuclear spins will try to align with the external magnetic field, and the spin 
10
will be oriented either parallel or antiparallel to the magnetic field as 
illustrated in Fig. 2.2. 





, so the interaction energy will split into ܧേଵ/ଶ ൌ  טߛ԰ܤ଴/2 for 
two different ݉ states and the energy difference between these two states is 
∆ܧ ൌ  ߛ԰ܤ଴. In thermal equilibrium at temperature T, the numbers of the 







ൌ expሺ∆ܧ/݇ܶሻ      . . . . ሺ2.13ሻ 
where േܰଵ/ଶ  are the numbers of the spins in ݉ ൌ േ
ଵ
ଶ
 states, k is the 
Boltzmann constant. Because for most cases in medical imaging, the 
temperature, T, is at body temperature of 310 K or room temperature of 298 
K, ∆ܧ is much smaller than ݇ܶ, a high-temperature approximation can be 
applied to equation 2.13 as  
ଵܰ/ଶ
ିܰଵ/ଶ






      . . . . ሺ2.14ሻ 
Associated with 
ଵܰ/ଶ ൅ ିܰଵ/ଶ ൌ ܰ     . . . . ሺ2.15ሻ 









plitting of a spin 1/2 system in the pre
 
sence of an 
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      . . . . ሺ2.16ሻ 
Therefore, in a sample of N spins, there are number ܰ · ఊ԰஻బ
ଶ௞்
 more spins 
oriented parallel than antiparallel to the external magnetic field.  













̂ݖ     . . . . ሺ2.17ሻ 
According to quantum mechanics, the projections on the x-y plain of each spin 
magnetic moment ߤሬറ௡  have random phase, which makes the two terms 




























̂ݖ     . . . . ሺ2.18ሻ 
which complies with Curie’s law ܯሬሬሬറൌ ܥ ·ܤሬሬറ/ܶ  with the Curie constant ܥ ൌ
 ܰߛଶ԰ଶ/4݇. 
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Since each single spin magnetic moment follows equation 2.2, it would 




 ൌ ܯሬሬሬറ ൈ  ߛ ܤሬሬറ     . . . . ሺ2.19ሻ 
2.4 Signal Excitation 
2.4.1 Rotating Frame 
The results in previous sections were derived in the laboratory frame. 
To simplify the description of excitation, we first introduced the concept of a 
rotating frame. If we move into a frame that rotates about ܤሬሬറ଴ with angular 
velocity Ωሬሬሬറ, ߤሬറ can be expressed in the new frame as ߤሬറ ሺݐሻ ൌ ߤ௫ሺݐሻݔො ′ ൅ ߤ௬ሺݐሻݕො ′ ൅








ൌ Ωሬሬሬറ ൈ ݔො ′
݀ݕො ′
݀ݐ
ൌ Ωሬሬሬറ ൈ ݕො ′
݀̂ݖ ′
݀ݐ
ൌ Ωሬሬሬറ ൈ ̂ݖ ′





































൅Ωሬሬሬറ ൈߤሬറ ሺݐሻ     . . . . ሺ2.21ሻ 
where ఋఓሬሬറሺ௧ሻ
ఋ௧




ൌߤሬറൈ ߛ ܤሬሬറ൅ߤሬറൈΩሬሬሬറ ൌߤሬറൈ ߛሺܤሬሬറ൅
Ωሬሬሬറ
ߛ
ሻ     . . . . ሺ2.22ሻ 
In this rotating frame, the spin magnetic moment ߤሬറ experiences an 
effective field ܤሬሬറ௘௙௙ൌܤሬሬറ൅Ωሬሬሬറ/ߛ, which ߤሬറ precesses about. 
2.4.2 Classical Description 
If an alternating magnetic field is turned on along the x-axis as  ܤሬԦଵ ൌ
ݔොܤଵ cosωt, it can be decomposed as the sum of two rotating magnetic fields,  








ܤଵሺݔො cos߱ݐ ൅ ݕො sin߱ݐሻ     . . . . ሺ2.23ሻ 
࡮ሬሬറࢉ࢒  and ࡮ሬሬറࢉࢉ  are the components rotating clockwise and counterclockwise 
about the z-axis (as seen from the positive side of the z-axis) with angular 
frequency ࣓. Because ࡮ሬሬറࢉࢉ rotates at an angular frequency different from the 
magnetization ࡹሬሬሬറ  by ࣓൅࣓૙ , ࡮ሬሬറࢉࢉ  is far from resonance with ࡹሬሬሬറ  and can be 
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ൌ expሺെ݅߱ݐܫ௭ሻ ሺെ݅ܫ௭ܫ௬ ൅ ݅ܫ௬ܫ௭ሻ expሺ݅߱ݐܫ௭ሻ 
ൌ െexpሺെ݅߱ݐܫ௭ሻ ܫ௫ expሺ݅߱ݐܫ௭ሻ 
ൌ െܣ     . . . . ሺ2.26ሻ 
By solving the differential equation ௗ
మ஺
ௗሺఠ௧ሻమ
ൌ െܣ,  
ܣሺ߱ݐሻ ൌ ܫ௫ cos߱ݐ ൅ ܫ௬ sin߱ݐ       . . . . ሺ2.27ሻ 
combined with the definition of function ܣሺ߱ݐሻ, 
expሺെ݅߱ݐܫ௭ሻ ܫ௫ expሺ݅߱ݐܫ௭ሻ ൌ ܫ௫ cos߱ݐ ൅ ܫ௬ sin߱ݐ       . . . . ሺ2.28ሻ 
Substitute this into equation 2.25, 
࣢ ൌ െߛ԰ሾܤଵ expሺെ݅߱ݐܫ௭ሻ ܫ௫ expሺ݅߱ݐܫ௭ሻ ൅ ܤ଴ܫ௭ሿ     . . . . ሺ2.29ሻ 






࣢߰ ൌ ݅ߛሾܤଵ expሺെ݅߱ݐܫ௭ሻ ܫ௫ expሺ݅߱ݐܫ௭ሻ ൅ ܤ଴ܫ௭ሿ߰     . . . . ሺ2.30ሻ 
Substitute  ߰ with ߰′ ൌ expሺ݅߱ݐܫ௭ሻ ߰,  
߲߰′
߲ݐ
ൌ ݅ሾߛܤଵܫ௫ ൅ ሺ߱ ൅ ߛܤ଴ܫ௭ሻሿ߰′     . . . . ሺ2.31ሻ 
by doing so, we are actually moving into a rotating frame ߰′ can be obtained 




ൌ ݅ߛܤଵܫ௫߰′     . . . . ሺ2.32ሻ 
The solution is  
߰′ሺݐሻ ൌ expሺ݅ߛܤଵܫ௫ݐሻ߰′ሺ0ሻ     . . . . ሺ2.33ሻ 
Since ߰′ሺݐሻ ൌ expሺ݅߱ݐܫ௭ሻ ߰ሺݐሻ and ߰′ሺ0ሻ ൌ ߰ሺ0ሻ, 
߰ሺݐሻ ൌ expሺെ݅߱ݐܫ௭ሻ expሺ݅ߛܤଵܫ௫ݐሻ߰ሺ0ሻ     . . . . ሺ2.34ሻ 
Therefore,  
ۃߤ௭ሺݐሻۄ ൌ න߰כሺݐሻߤ௭߰ሺݐሻ ݀߬ 
ൌ නexpሺ݅߱ݐܫ௭ሻ expሺെ݅ߛܤଵܫ௫ݐሻ߰כሺ0ሻߛ԰ܫ௭ expሺെ݅߱ݐܫ௭ሻ expሺ݅ߛܤଵܫ௫ݐሻ߰ሺ0ሻ ݀߬ 
ൌ ߛ԰න߰כሺ0ሻexpሺെ݅ߛܤଵܫ௫ݐሻ ܫ௭ expሺ݅ߛܤଵܫ௫ݐሻ߰ሺ0ሻ ݀߬     . . . . ሺ2.35ሻ 
Similar to derivation of equation 2.28,   
expሺെ݅ߛܤଵܫ௫ݐሻ ܫ௭ expሺ݅ߛܤଵܫ௫ݐሻ ൌ ܫ௭ cos ߛܤଵݐ െ ܫ௬ sin ߛܤଵݐ       . . . . ሺ2.36ሻ 
Thus 
ۃߤ௭ሺݐሻۄ ൌ  ߛ԰න߰כሺ0ሻ൫ܫ௭ cos ߛܤଵݐ െ ܫ௬ sin ߛܤଵݐ൯߰ሺ0ሻ ݀߬ 
ൌ ۃߤ௭ሺ0ሻۄ cos ߛܤଵݐ       . . . . ሺ2.37ሻ 
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The result above shows ۃߤ௭ሺݐሻۄ oscillates in time, which satisfies the 
results derived classically - z magnetization rotates about ݔො ′  axis in the 
rotating frame. 
2.5 Spin – Lattice Relaxation Time 
Spin – lattice relaxation time, T1, is the characteristic time of the 
process that the spin system reestablishes the thermal equilibrium 






      . . . . ሺ2.38ሻ 
Once a spin is excited to a higher energy state from the ground state, it 
will always give up the energy and go back to the ground state eventually. 
Generally there are two mechanisms to realize the transition from excitation 
state to ground state – spontaneous and stimulated emissions. Because the 
spontaneous emission rate is proportional to the cube of the absorption 
energy, and the typical NMR absorption energy is in the order of ߤܸ݁, the 
rate of spontaneous emission in NMR system is almost zero. Therefore, 
stimulated emission is the dominant mechanism for the transition of excited 
nuclear spins. 
For a specific nucleus to achieve stimulated emission, an 
electromagnetic field oscillating at its Larmor frequency is required, which 
means the photon energy of the electromagnetic wave must be equal to the 
energy gap between its excitation state and ground state. 
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In general, for water hydrogen, the major source of the electromagnetic 
field is the magnetic field created by the neighboring hydrogen nuclear spin 
within the same water molecule, and the strength of the magnetic field is 
about 5 Gauss. Because of the thermal fluctuating random motion of the 
translation, rotation and vibration of the water molecule itself, and 
intermolecular collisions, the local magnetic field changes constantly in 
magnitude and direction, therefore becoming time varying. Taking the 
Fourier-transformation of this time varying magnetic field, one can get the 
spectral density ܬሺ߱ሻ , which can be considered as the density profile of 
molecules tumbling at different frequency.  ܬሺ߱ሻ is related to the correlation 




      . . . . ሺ2.39ሻ 
Fig. 2.5 gives ܬሺ߱ሻ curves of three different ߬௖. For free water where 
water molecules freely move around, the random motion of the water 
molecules is fast with a tumbling frequency of about 1011 Hz (5), which 
corresponds to the short ߬௖  curve. Since the proton Larmor frequency is 
1.27×108 Hz at 3T, which is much lower than 1011 Hz, there is only a small 
portion of spectral density at the proton Larmor frequency. For water in soft 
tissues, due to the increased size of macromolecules, molecular tumbling is 
slowed down, i.e., ߬௖ becomes larger depending on the medium. In solid, water 
molecules are highly restricted, and ߬௖ is large. As shown in Fig. 2.5, 
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 Figure 2.5 The spectral density of different correlation times, ߬௖ , which 
corresponds to water molecules in different environment. 
 
compared with the intermediate ߬௖, there is relatively less molecule tumbling 
at the proton Larmor frequency for both short ߬௖ and long ߬௖, meaning less 
chance to take energy from the spin system and therefore longer T1. 
When paramagnetic T1 contrast agents are introduced into the water, 
the unpaired electrons of paramagnetic ions play a key role in the T1 
relaxation process (6). For example, the electron configuration of gadolinium 
atom in Gd3+ based contrast agent is  
1s2 2s2 2p6 3s2 3p6 4s2 3d10 4p6 5s2 4d10 5p6 6s2 4f7 5d1 
as shown in Fig. 2.6. When it loses three outer shell electrons and becomes 
Gd3+ ion, there are still seven unpaired electrons in its 4f shell. Since the 
interaction between two spin magnetic dipoles is proportional to the  
22
 Figure 2.6 The electron shell diagram of gadolinium. 
 
multiplication of the gyromagnetic ratios of both spins, the gyromagnetic 
ratio of the electron is roughly several hundred to one thousand times larger 
than the nuclear gyromagnetic ratio. Therefore, the interaction between 
electron spin and nuclear spin is much larger than it is between two nuclear 
spins.  
Due to the extreme toxicity of free gadolinium ion, when we use Gd3+ 
as a contrast agent, it is necessary to chelate it with some organic ligands, 
such as DTPA (diethylenetriaminepentaacetic acid). Since the dipole-dipole 
interaction is inversely proportional to the cube of the distance between two 
dipoles, to have effect on T1 relaxation of water proton, Gd3+ needs to be in 
close contact with water molecules, which is realized by the coordination 
binding between Gd3+ and water molecules. Gd3+ has nine coordination 
binding sites, in Gd-DTPA, eight of them are with DTPA, and there is only 
one left to interact with water molecules, as shown in Fig. 2.7. Since the 
binding is loose, water molecules can quickly attach to Gd3+, complete the 
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Because of the dipole-dipole interaction between nuclear spins, the 
exchange of spin-states between two adjacent spins can occur. During this 
energy exchange, the spins will go through the energy conserving flip-flop 
transitions. In this way, the spin polarization transfer occurs from one 
location to another without actual physical translation of nuclei, which is 
known as spin diffusion. 
In the bulk material, spins experience not only the magnetic field 
produced by an external magnet, but also the field from neighboring spins 
and the electron cloud around the nucleus.  The sum of these magnetic fields 
is the local magnetic fields at each spin location. Random motion of these 
neighboring spins creates variations of the local magnetic field and therefore 
different local Larmor frequencies. When spins diffuse from one location to 
another, due to the different local Larmor frequency, the spins will 
accumulate different phases. On a macroscopic level, the magnetization, 
which is the vector sum of the spin magnetic moments, will eventually decay 
to zero while the phase of spins becomes completely random. 
Because the time scale of molecule motion (on the order of picoseconds) 
is much smaller than T2 (µs ~ s), within the time scale of T2 relaxation, the 
spins will only see the average of the local magnetic field over this period. In 
general, the fluid molecules are less restricted than the molecules in solids. 
Therefore, the more active motion of the fluid molecules makes the time 
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average of the local field more uniform, which results in a longer T2 in fluids 
than in solids. 
2.7 The Bloch Equation 
In section 2.3, we have explored the behavior of nuclear magnetization 
in an external magnetic field (equation 2.19). Taking into account the spin-
lattice relaxation (equation 2.38) and spin-spin relaxation (equation 2.40), the 









      . . . . ሺ2.41ሻ 
which is the governing equation of motion for a magnetization. In a rotating 
frame, the equation (2.41) can be expressed as 
݀ ܯሬሬሬറ ′
݀ݐ






      . . . . ሺ2.42ሻ 
Bloch’s equation is very useful to describe the evolution of the 
magnetization under the influence of various magnetic fields, which include 
the static, spatially varying gradient, and RF magnetic fields.  
During the RF pulse, consider the on-resonance case that the angular 
frequency of the rotating frame equals to the Larmor frequency of the nuclear 
spins. The effective magnetic field will be simply the B1 field as, 
ܤሬሬറ௘௙௙ൌ ܤଵݔො′     . . . . ሺ2.43ሻ 
26
Since the excitation duration is generally short compared to T1 and T2, 
we can ignore the terms related to T1 and T2, and equation 2.42 can be 









ൌ െߛܤଵܯ௬′     . . . . ሺ2.44ሻ 
Solving equation 2.44, we get 
ܯ௫′ ൌ 0 
ܯ௬′ ൌ ܯ଴ sin ߛܤଵݐ 
ܯ௭′ ൌ ܯ଴ cos ߛܤଵݐ       . . . . ሺ2.45ሻ 
This result is the same as the result we derived in section 2.4. 
Immediately after the excitation, ܤሬሬറ௘௙௙  becomes zero in the same 
rotating frame, because of the absence of the excitation field. If we consider 












      . . . . ሺ2.46ሻ 
Solving equation 2.46, we have 
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ܯ௭′ ൌ ܯ଴ ൤1 െ exp ൬െ
ݐ
ଵܶ




൰      . . . . ሺ2.47ሻ 
where ݐ ൌ 0ା indicates the moment right after the excitation. 
2.8 Signal Detection 
According to Faraday’s law, equation 2.48, changing magnetic flux will 
induce an electromotive force (EMF) in a closed circuit, and the EMF will 




      . . . . ሺ2.48ሻ 
When the magnetization is excited, i.e., the magnetization is tipped 
from z direction onto the x-y plane, it will precess about the z-axis. For 
example, if we place a detection circuit in a plane perpendicular to the x-axis, 
as shown in Fig. 2.8, the x component of the precessing magnetization will 
oscillate in time, and then create an alternating magnetic flux through the 
area of the circuit, and therefore create an alternating current inside the 
circuit.  
Fig. 2.9 shows the general steps for NMR signal detection. Once the 
alternating current is generated in the RF coil, the current signal will be sent 
to a low noise preamplifier, then the amplified signal will be mixed with an 






































equivalent to moving into the rotating frame. At last, the signal is digitalized 
by an analog-to-digital converter (ADC) and sent to the computer for further 
processing, such as image reconstruction in MR imaging. 
2.9 Imaging Techniques 
2.9.1 Localization Techniques 
To acquire images, we need an ability to distinguish signals that 
originate from different spatial locations. The hardware introduced for this 
purpose is called gradient coils. A gradient coil assembly includes three sets 
of coils, which can generate different magnetic field distributions along the z 
axis – the main magnetic field direction, and make the main magnetic field 
depend on locations along three independent directions, say the x, y and z 
directions, as illustrated in Fig. 2.10. These three gradient coils generate 
three orthogonal linear gradient fields ܩ௫ , ܩ௬and ܩ௭ . Utilizing the gradient 
coils, there are three techniques to encode location information into the 
signals. They are slice selection, frequency encoding and phase encoding. A 
brief introduction of these techniques will be done as follows. 
If we turn on a gradient in the ̂ݖ direction, which can be any direction 
in practice, by combining three gradient coil sets as ො݊ ൌ ܩ௫ݔො ൅ ܩ௬ݕො ൅ ܩ௭̂ݖ, the 
main magnetic field ܤ will have z dependence ܤ ൌ ܤ଴ ൅ ܩ௭ݖ with a constant ܩ௭, 
therefore, the Larmor frequency ߱଴ ൌ  ߛܤ଴ will also depend on z. As shown in 
Fig. 2.11, when the excitation pulse only covers a certain bandwidth of 





























contribute to the signal, while spins from all other locations give no signal. 
The technique is called slice selection. 
If we assume that the main magnetic field is perfectly uniform within 
the region of the subject we are studying, then without any gradient fields, 
the spins from the entire subject will have the same Larmor frequency. The 
NMR signal, which is the sum of all individual magnetizations, is given by 
equation 2.49. Here, ߩ is the spin density at the position x. 
ܵሺݐሻ ൌ නߩሺݔሻ expሺെ݅ߛܤ଴ݐሻ ݀ݔ ൌ නߩሺݔሻ expሺെ݅߱଴ݐሻ ݀ݔ       . . . . ሺ2.49ሻ 
When the z-component of the magnetic field linearly varies along the x-
axis by turning on ܩ௫ , the magnetic field becomes position dependent as, 
ܤሬሬറൌ ܤ଴ ൅ ܩ௫ݔ, so is the Larmor frequency of the spins as ߱ ൌ ߱଴ ൅ ߛܩ௫ݔ. The 
signal can be expressed as, 
ܵሺݐሻ ൌ නߩሺݔሻ expሺെ݅߱଴ݐሻ exp ሺെ݅ߛܩ௫ݔݐሻ݀ݔ       . . . . ሺ2.50ሻ 
In the rotating frame, the term expሺെ݅߱଴ݐሻ is removed and the equation 2.50 
becomes simplified as, 
ܵሺݐሻ ൌ නߩሺݔሻ exp ሺെ݅ߛܩ௫ݔݐሻ݀ݔ       . . . . ሺ2.51ሻ 
Let ݇௫ ൌ ܩ௫ݐ, the equation 2.51 can be rewritten as  
ܵሺݐሻ ൌ නߩሺݔሻ exp ሺെ݅ߛ݇௫ݔሻ݀ݔ       . . . . ሺ2.52ሻ 
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After Fourier transform,  
ߩሺݔሻ ൌ නܵሺݐሻ exp ሺ݅ߛ݇௫ݔሻ݀݇௫       . . . . ሺ2.53ሻ 
If we turn on the gradient, e.g., ܩ௬  along y direction, for a time T, 
because the spins at different locations will have different Larmor frequency, 
they will accumulate different phases ߛܩ௬ݕܶ. Let ݇௬ ൌ ܩ௬ܶ, in the rotating 
frame, 
ܵሺݐሻ ൌ නߩሺݕሻ exp ሺെ݅ߛ݇௬ݕሻ݀ݔ       . . . . ሺ2.54ሻ 
After Fourier transform,  
ߩሺݕሻ ൌ නܵሺݐሻ exp ሺ݅ߛ݇௬ݕሻ݀݇௬       . . . . ሺ2.55ሻ 
Therefore, by using these methods, the signal contribution from 
different locations can be separated from each other and all together present 
an image in the spatial domain. 
2.9.2 Imaging Pulse Sequences 
Fig. 2.12 shows the schematic diagram of a spin echo pulse sequence. 
In the rotating frame, the magnetization initially lies along the z’ axis. After 
a 90° RF pulse, the magnetization is flipped to the x’-y’ plane, say along the y’ 
axis, and starts to dephase due to the non-uniform local magnetic field. At 
time t=TE/2, the isochromats with different Larmor frequency have 
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Figure 2.12 The pulse sequence diagram of a spin echo sequence. 
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accumulated different amounts of phase angle ߶. During the moment, a 180° 
RF pulse is turned on, the phase angle ߶ becomes –߶. Another time t=TE/2 
later, all the isochromats will be refocused along the y’ axis and a spin-echo is 
formed, as shown in Fig. 2.13. At the echo time t=TE, the signal will be 
collected to reconstruct the images. 
Echo Planar Imaging (EPI) is a high speed imaging technique, in 
which multiple FID data with different ky encodings are measured after a 
single excitation. A pulse sequence diagram of a spin echo type EPI sequence 
is presented in Fig. 2.14. The main difference between normal spin echo and 
a spin echo EPI sequence is the way k-space is filled. For normal spin echo, 
the signal collected at t=TE fills only one line of k-space, while for spin echo 
EPI, using a time varying gradient, the signal collected at t=TE can fill the 
entire k-space in a single shot. Only one echo is positioned at the spin-echo 
position and the rest are T2*-weighted gradient echoes. The corresponding k-







 Figure 2.13 The diagram shows how the isochromats are being excited after 
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RAPID SIMULTANEOUS ACQUISITION OF T1 AND T2 
MAPPING IMAGES USING MULTISHOT DOUBLE 
SPIN-ECHO EPI AND AUTOMATED  
VARIATIONS OF TR AND 
 TE (MS-DSEPI-T12) 
This chapter is based on the paper “Rapid simultaneous acquisition of 
T1 and T2 mapping images using multishot double spin-echo EPI and 
automated variations of TR and TE (ms-DSEPI-T12),” which was published 
in the journal NMR in Biomedicine in 2010, authored by Xin Liu, Yi Feng, 
Zheng-Rong Lu, Glen Morrell and Eun-Kee Jeong. 
3.1 Introduction 
Dynamic contrast enhanced MRI (DCE-MRI) has shown promise in 
detection and characterization of various tumors (1-8). DCE-MRI may 
provide information about important perfusion parameters such as vessel 
permeability (9), microvessel density (10), and washout which may allow 
more accurate characterization of benign versus malignant neoplasms. 
Change in relaxation rate ΔR1 (R1 = 1/T1) is linearly related to Gd-DTPA 
concentration over a range of concentrations (11-13), and can be used to 
 
estimate Gd-DTPA concentration. Pharmacokinetic information can be 
obtained from the time-variation of ΔR1(ݎറ). Change in T2 relaxation time is 
not usually measured in DCE MRI, because of the extended acquisition time 
which conventional T2 measurement would require. However, the change of 
the concentration of the gadolinium based contrast agent causes the changes 
in both T1 and T2 relaxation times (14).  The change in T2 may be negligible 
at low concentration, but at higher concentration T2 shortening may 
introduce error in the measurement of T1. This effect may become significant 
in tumors, in which contrast achieves high concentrations due to high vessel 
density and blood supply induced by the tumor growth (15). 
Spin echo or gradient recalled echo sequences with either inversion-
recovery (IR) or saturation-recovery (SR) have been used for accurate T1 and 
T2 measurements. Their use has been limited to nondynamic imaging 
because of their long imaging times. Several alternative methods for T1 
mapping have been presented including 2D singleshot-EPI (2D ss-EPI) and 
variants (Look-Locker EPI, IR-EPI) which achieve better simultaneous 
spatial and temporal resolution (16-17). However, the spatial resolution using 
these rapid imaging methods is limited by susceptibility artifact (18-19). A 
multishot spin-echo EPI (ms-SEPI) sequence may be used to trade off 
imaging speed with severity of susceptibility artifact. Gradient-echo imaging 
with flip angle variation, may be used with reasonable temporal and spatial 
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resolutions (20). However, T1 estimates obtained by this method are sensitive 
to RF inhomogeneity. 
We present a rapid MR imaging method to simultaneously measure T1 
and T2 using a multishot double spin-echo EPI sequence with automated 
variation of TR and TE (ms-DSEPI-T12) (21-22). Ms-DSEPI-T12 allows 
flexible adjustment of echo train length to compensate for differing severity of 
susceptibility artifact when imaging different areas of the body.  
Simultaneous measurement of T1 and T2 allows correction of T2 effects on T1 
measurement.  Our method is able to accurately measure T1 with high spatial 
and temporal resolution, making it applicable to dynamic measurement of 
contrast concentration for pharmacokinetic studies. 
3.2 Materials and Methods 
3.2.1 Pulse Sequence Description 
A multishot spin-echo EPI (ms-SEPI) sequence was used to implement 
the acquisition of the second echo and the automatic variations of the TR and 
TE on a Siemens 3T Trio clinical imaging system (Siemens Medical Solution, 
Erlangen, Germany). The schematic RF diagram of ms-DSEPI-T12 is shown 
in Fig. 3.1. The sequence begins with a presaturation pulse, followed by a 
saturation recovery delay interval τ. A 90-180° RF pulse pair is then played 
and a spin echo is acquired with echo-planar gradients scanning a portion of 
the k-space of a single slice, at minimum echo time.  Then a second 180° is 
applied at a variable second echo time TEi, and the same portion of k-space is 
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 Figure 3.1. Pulse sequence diagram. τi is the saturation recovery time generating 
the ith point on the T1 recovery curve for estimation of T1. TEi is the echo time for 
the second echo, which is incremented as τ is incremented to give a set of second-
echo images with varying T2 weighting for T2 estimation.  Echotrain length after 
each 180° refocusing pulse is determined based on the desired acquisition speed and 
tolerated amount of image distortion, with longer echo train lengths giving shorter 
imaging time but more severe distortion secondary to susceptibility shifts. Each 
group of n TR’s enclosed within a round bracket represents a complete k-space 
acquisition, giving an image for a particular recovery time τi (at minimum echo time 
TE0) and a second image for a particular second-echo echo time TEn. The series of 
TR’s within the curly bracket is repeated to give T1 and T2 maps at different 






reacquired.  The sequence is repeated with no change in sequence timing to 
segmentally fill in the k-space for two complete images. This procedure is 
repeated with different saturation recovery times τi to create additional 
images. Each of the first-echo images supplies a time point along the T1 
recovery curve for estimation of T1. The echo time TEi of the second spin echo 
is incremented at the same time that the saturation recovery time is 
incremented. This creates a series of second echo images with differing T2 
weighting from which T2 can be estimated. After a complete set of first- and 
second-echo images are obtained with varying recovery times τi and second 
echo times TEi, the entire process is repeated to provide T1 and T2 estimates 
at successive time points, to allow analysis of enhancement kinetics. 
The initial saturation pulse was performed with an adiabatic 
excitation followed by a gradient dephasing lobe.  Better saturation may be 
obtained with a series of multiple saturation pulses and dephasing gradient 
lobes if needed. 
Assuming that the longitudinal magnetization is completely destroyed 
by the saturation pulses at the beginning of the sequence, the signal 
equations for the first and second echoes for a given saturation recovery time 
τi and second echo time TEi are: 
first echo:    





మ்ሺ௥റሻ     . . . . ሺ3.1ሻ 
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second echo:  






మ்ሺ௥റሻ     . . . . ሺ3.2ሻ 
A sequence of first echoes with various saturation times τi is used to 
calculate T1, while a sequence of second echoes with various echo times TEi is 
used to calculate T2.   Equations 3.1 and 3.2 can be written as: 
ଵܵሺݎറ|߬௜, ܶܧ଴ሻ ൌ ܵᇱ଴ሺݎറሻ · ൬1 െ ݁
ି
ఛ೔
భ்ሺ௥റሻ൰ , ܵᇱ଴ሺݎറሻ ൌ ܵ଴ሺݎറሻ · ݁
ି ்ாబ
మ்ሺ௥റሻ     . . . . ሺ3.3ሻ 
ܵଶሺݎറ|߬௜, ܶܧ௜ሻ ൌ ܵ"଴ሺݎറሻ · ݁
ି
்ா೔
మ்ሺ௥റሻ, ܵ"଴ሺݎറሻ ൌ ܵ଴ሺݎറሻ · ൬1 െ ݁
ି
ఛ೔
భ்ሺ௥റሻ൰      . . . . ሺ3.4ሻ 
In the above equations, ܵ଴ሺݎറሻ  represents the equilibrium longitudinal 
magnetization. The equilibrium signal ܵ଴ሺݎറሻ at a position ݎറ does not vary with 
T1 and therefore does not change after administration of contrast, but 
depends on proton density, imaging voxel dimension, magnetic field strength, 
and temperature (23). ܵᇱ଴ሺݎറሻ is the signal intensity that would be obtained at 
the first echo time TE0 after complete saturation recovery, i.e., for τi = ∞. 
ܵᇱ଴ሺݎറሻ is also independent of T1 and can be measured once during precontrast 
imaging with a long recovery time τ (~ 5T1) and then used as a data point in 
the calculation of T1 for each subsequent time point in the sequence of 
dynamic images without being measured again. ܵ"଴ሺݎറሻ is the signal intensity 
that would be obtained for a given saturation recovery time τi with no T2 







































3.2.2 Calculation of T2 Using the Second Echoes 
As shown in Fig. 3.2, both precontrast T20 and dynamic T2 can be 
estimated from the sequence of second echoes ܵଶሺ߬௜, ܶܧ௜ሻ, each of which was 
obtained at a different echo time ܶܧ௜ .  A first echo ଵܵሺ߬ଵ, ܶܧ଴ሻ can also be 
included in the points to be fitted for T2 estimation.  Because each second 
echo was obtained after a different saturation recover time ߬௜, the second echo 
signal ܵଶ is dependent on T1.  To remove this dependence, the second echo 
signal intensity ܵଶሺ߬௜, ܶܧ௜ሻ  is normalized by the first echo time signal 
ଵܵሺ߬௜, ܶܧ଴ሻ for the same ߬௜.  T2 estimation was performed with least-squares 
fitting of the signal intensity samples to monoexponential decay. 
3.2.3 Calculation of T1 Using the First Echoes  
The sequence of first echo images ଵܵሺݎറ|߬௜, ܶܧ଴ሻ traces the saturation 
recovery of longitudinal magnetization at various recovery times ߬௜ .  For 
dynamic T1 imaging, a limited number of saturation recovery times are 
measured, typically three or four, so that T1 can be estimated in a short time 
to allow measurement of T1 at multiple closely spaced time points.  More 
saturation recovery times may be acquired during precontrast imaging.  This 
allows accurate estimation of the fully recovered signal intensity ܵᇱ଴ሺݎറሻ.  This 
signal intensity does not change with T1 shortening after administration of 
contrast, and can be used as an additional data point for estimation of T1 at 
later time points without being measured at these time points.  However, 
ܵᇱ଴ሺݎറሻ may change from its precontrast value on postcontrast scans because of 
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the T2 shortening effect of contrast, causing a variable degree of T2 decay 
during the fixed first echo time TEo.  Because T2 is being simultaneously 
measured by our sequence, the effect of altered T2 on ܵᇱ଴ሺݎറሻ can be easily 
removed. 
3.2.4 Calculation of ΔR1 Map Using T1 Map 
The dynamic change in ∆ܴଵሺݎറ, ݐሻ at positionݎറ and time point t can be 
used to understand the kinetics of the delivery of the contrast agent based on 






ଵܶሺݎറ, ݐ ൌ 0ሻ
      . . . . ሺ3.5ሻ 
The calculation of T1, T2 and ΔR1 for the acquired data was performed 
pixel-by-pixel, using custom mapping software developed in IDL (Interactive 
Data Language, Boulder, CO). The nonlinear Levenberg-Marquardt curve-
fitting algorithm and an exponentially decaying fit were used to calculate T1 
and T2, respectively. T1, T2, and ܵᇱ଴ሺݎറሻ of the precontrast data were calculated. 
For dynamic data, the spin-spin relaxation time T2 was calculated after 
removing T1 recovery effect from the second echo images. Then, this T2 value 
was used to eliminate T2 decay effect from ܵᇱ଴ሺݎറሻ that was obtained from the 




3.2.5 MR Imaging Experiments 
All MR imaging experiments were performed on a clinical 3 T MRI 
system (Trio TIM System, Siemens Medical Solution, Erlangen, Germany). 
To validate the signal normalization process to remove T1 recovery effect in 
T2 measurement data, the ms-DSEPI-T12 mapping sequence was performed 
on a phantom filled with 0.1 mMol MnCl2 solution, using a transmit/receive 
head coil. First, the sequence was run with the following schedule of 
saturation recovery times τi: 0.2, 0.25, 0.4, 0.8, 1.4, 2.2, 3.2 and 5.0 s.  The 
first echo time TE0 was 11.6ms, and the schedule of second echo times was: 
TEi = (15.1 + 10i) ms, i = 1,2,…8.  This sequence was then repeated with a 
fixed saturation recovery time of 5.0 s, with the same schedule of TEi’s. An 
echotrain length (ETL) of 7 with 75 % asymmetric sampling was used for all 
phantom imaging, which resulted in the actual ETL of 5. 
An MRI experiment was performed with three phantoms that were 
constructed of identical glass bottles with different MnCl2 concentrations of 
0.1, 0.3, and 0.6 mMol. Each bottle was filled with the same amount of 
solution to have equal coil loading. MR imaging was separately performed on 
each bottle positioned at the center of the head coil, using ms-DSEPI-T12 
with imaging matrix 128×64, inplane spatial resolution 1.5×1.5 mm2, and 
slice thickness 4.0 mm for 3 slices, saturation recovery times τi=0.09, 0.16, 
0.25, 0.44, 0.73, 1.52, 2.31, 5.9 s and echo times TE0=11 ms, TEi = (13 + 10i) 
ms, total imaging time 4 min 47 s. After imaging the first bottle, the second 
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and third bottles were placed in turn in the same location and separately 
imaged. 
To evaluate the performance and accuracy of the new method, the 
same phantom was used to acquire T1 measurement data with (1) ms-DSEPI-
T12 for T1 and T2, (2) conventional inversion-recovery spin-echo (IR-SE) for T1, 
and (3) conventional turbo-spin-echo (TSE) for T2 measurements. For the ms-
DSEPI-T12 sequence, imaging matrix was 128×64, inplane spatial resolution 
was 2.0×2.0 mm2, and slice thickness was 3.0 mm for 5 slices, the schedule of 
saturation recovery times for the ms-DSEPI-T12 sequence was τi=0.22, 0.46, 
0.7, 0.94, 1.33, 1.92, 2.91 and 4.9 s, with TE0=10.0 ms and TEi = (12.7 + 10i), i 
= 1 ~ 8. For the inversion-recovery sequence and the TSE sequence, the same 
imaging matrix 128×64, inplane spatial resolution 2.0×2.0 mm2, and slice 
thickness 3.0 mm for 5 slices was used. The inversion times TI used for the 
inversion-recovery sequence were 0.1, 0.4, 0.55, 0.6, 0.7, 0.8, 1.5 and 3.0 s 
with TR 10 s and TE 17 ms. TEs of 12, 23, 35, 47, 59, 70, 83, 94 and 105 ms 
were used for the TSE sequence with 5 s TR and ETL 9 to acquire T2 maps. 
The imaging time for T1 measurement was 5 min 36 s for ms-DSEPI-T12 
measurement, while it was 16 min 39 s for IR-SE. The imaging time of T2 
measurement was 6 min 18 s for the TSE sequence. 
The ms-DSEPI-T12 sequence was used to perform dynamic contrast 
enhanced T1 measurement in mice.  Female athymic nude mouse was cared 
for under the guidelines of a protocol approved by the University of Utah 
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Institutional Animal Care and Use Committee. The MDA-MB-231 human 
breast cancer cell line was purchased from the American Type Culture 
Collection (ATCC, Manassas, VA) and cultured in Leibovitz’s L-15 medium 
with 2 mM L-glutamine and 10 % FBS at 37 °C in a humidified atmosphere 
of 5 % CO2. The cells were allowed to grow to about 90 % confluence and then 
resuspended in DMEM medium. The cell number was adjusted to 106 
cells/ml, and the cells were mixed with an equal volume of Matrigel (Becton-
Dikinson, Franklin Lakes, NJ). The Matrigel mixtures, containing 
approximately 2×105 cells in 0.2 ml, were implanted subcutaneously in the 
flanks of the mouse. Each implantation generated a tumor. Tumor size 
reached 0.5–1.5 cm in diameter 21 days after cell implantation. 
The ms-DSEPI-T12 sequence was applied to acquire dynamic images 
in the axial plane with echotrain length of 3, imaging matrix 64×28, inplane 
spatial resolution 1.0×1.0 mm2, and slice thickness 2.0 mm, for 4 slices. A 
Siemens human wrist coil was used.  Precontrast T1 mapping data were 
acquired with 8 different saturation recovery times τi=0.25, 0.5, 0.75, 1.0, 1.4, 
2.2, 3.2, and 5.0 s, first echo TE of 8ms, and second echo times of TEi = (9 + 
10i) ms, the imaging time was 2 min 56 s. For postcontrast dynamic imaging, 
TRs of 200, 500, and 750 ms and TE0=8 ms, TEi = (4 + 15i) ms were used. The 
imaging time for each time point was 15.0 s. Slice interleaving was limited by 
the shortest TR, i.e., 200 ms in the current protocol. 
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3.3 Results and Discussion 
The plots in Fig. 3.3 show the signal intensities of the second echoes of 
the fixed (◊) and the variable (*) recovery times, and after normalization (□) 
by the signal intensities of the first echoes. The normalized signal intensity 
values (□) obtained with variable saturation recovery times τi match the 
second echo signal intensities obtained with the constant saturation recovery 
time of 5 s, demonstrating that the effect of varying saturation recovery time 
on T2 estimation has been successfully removed. 
 The series of three phantom studies simulates the effect of imaging a 
single structure with time-varying T1. Prescan calibration was performed 
only for the first bottle and transmitter and receiver gains were held constant 
for the remaining bottles. 
T2 was estimated for the three bottles as described above. The 
equilibrium signal ܵᇱ଴ሺݎറሻ for the first bottle was measured at long saturation 
recovery time (5.9 s). This value was then combined with the measured T2 of 
each bottle to give a calculated value for the equilibrium value ܵᇱ଴ሺݎറሻ for each 
bottle, which was compared to the actual measured value. There was 
excellent agreement between the measured equilibrium values ܵᇱ଴ሺݎറሻ of the 
second and third bottles and the values calculated from ܵᇱ଴ሺݎറሻ of the first 
bottle and the T2 of each bottle, as shown in Table 3.1. This result confirms 
that the equilibrium value ܵᇱ଴ሺݎറሻ can be measured once in the precontrast 
phase of a dynamic contrast enhanced imaging experiment and then used to 
51
 Figure 3.3. Phantom study validating correction of second echo intensity for varying 
saturation recovery time.  Stars represent uncorrected second echoes, squares 
represent second echoes normalized by first echoes to remove effects of variable 
saturation recovery times, and diamonds represent second echoes obtained with 
constant saturation time of 5s.  Normalization removes the effect of varying 






Table 3.1. Measured vs. calculated equilibrium signal intensity ??????, representing 
the signal intensity measured at very large saturation recovery time (τi → ∞).  Good 
agreement between calculated and measured values shows that this point can be 





T2 (ms) So’(r) (calculated) So’(r) (measured) 
0.1 57.1±5.5 - 2196.2±60.3 
0.3 29.7±2.6 1838.6±50.5 1864.3±50.7 




calculate ܵᇱ଴ሺݎറሻ  for subsequent postcontrast time points, without actually 
being measured at these later time points. As demonstrated in Fig. 3.4, T2 
effects of increasing contrast concentration cause marked decrease in the 
equilibrium signal ܵᇱ଴ሺݎറሻ as well as T1 shortening. 
An MR imaging experiment was performed on a fluid phantom to 
compare the T1 relaxation times calculated from a data set of 8 well spaced 
saturation recovery times and a set with three short and one long saturation 
recovery times, which would represent the precontrast and the dynamic data 
sets of a dynamic contrast enhanced study.  Postcontrast measurement at a 
limited number of saturation recovery times allows better temporal 
resolution in the T1 estimation for dynamic imaging.  Shorter saturation 
recovery times allow shorter TR and therefore faster imaging.  The longest 
saturation recovery time point can be calculated from the precontrast data 
and the T2 of the current acquisition, substantially shortening the required 
imaging time. The measured signal intensities for varying saturation 
recovery times τi are shown in Fig. 3.5. The solid line represents the T1 
recovery curve fit to all eight data points.  The dashed line represents the T1 
recovery curve fit to only the first three data points plus the last data point. 
The resultant T1 values were 445.0±2.1 and 440.0±3.1 ms with the full (8 τi’s) 
and the partial (3 measured τi’s and 1 calculated from precontrast T1/T2 
measurements) data sets, respectively. The fractional difference between the 
resultant T1 values of two methods was less than 2 %. This experiment shows 
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Figure 3.4. Plots of the measured signal intensities for three concentrations of 
MnCl2 solutions. Increasing concentration gives faster T1 recovery but lower 
equilibrium signal intensity ?????? because of T2 shortening.  As shown in Table 3.1, 
the last time point (5.9 s in the above plots) can be measured at one concentration 
and then calculated for the other concentrations, significantly shortening the 














 Figure 3.5. T1 recovery plot of eight saturation recovery times, with T1 recovery 
curve fitted to all eight points (dashed line) vs. only the first three points and the 
last point (dotted line).  The solid line represents fitting to only the first three points 
without the last point, showing the necessity of the last point for accurate T1 
estimation.  However, this last point does not need to be measured during 
postcontrast dynamic imaging but instead can be calculated from its precontrast 
value and the measured T2. Plot b) is an enlarged view of plot a). 
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that the accurate value of T1 can be measured using only a few short τi’s and 
the semiempirical ܵᇱ଴ሺݎറሻ for rapid dynamic MR imaging. 
The T1 profiles along the dotted line on T1 maps of a fluid phantom in 
Fig. 3.6a using ms-DSEPI-T12 and IR-SE are overlaid in Fig. 3.6b. The mean 
values of T1 and T2 in a region-of-interest at the center of the object were 
measured as 867.9±34.1 ms and 872.0±5.9 ms using ms-DSEPI-T12 and IR-
SE, and 57.6±2.0 ms and 76.1±2.8 ms using ms-DSEPI-T12 and TSE, 
respectively. T2 value measured using ms-DSEPI-T12 was 24.3% lower than 
that measured using TSE. Both methods used a similar range of echo time 
TEs, 10 ~ 94 ms for ms-DSEPI-T12 and 12 ~ 105 ms for TSE. T1 relaxation 
time measured by the two methods was nearly equal, although the variance 
was somewhat increased in ms-DSEPI-T12 technique, particularly near the 
edge and outside of the RF coil. This was because the SNR in the source T1 
and T2 weighted images were significantly reduced in ms-DSEPI-T12 images 
compared to IR-SE images due to the short imaging time.  
The dotted rectangular box in Fig. 3.6a indicates the position of the coil. 
The homogeneity of the B1 field was poor near the right end of the coil. Since 
the phantom is uniform across the dotted line, the uniform T1 values across 
the dotted line measured using ms-DSEPI-T12 indicates that ms-DSEPI-T12 
would not suffer much from the RF inhomogeneity, except for the increased 




Figure 3.6. The profiles of T1 values measured along a central line on T1 maps of a 
phantom acquired with the ms-DSEPI-T12 mapping sequence (dotted line) and IR-
SE (solid line). The dotted rectangular box on the T1 map image (a) indicates the 




















Phantom studies demonstrated excellent agreement between the 
measured T1 values measured using ms-DSEPI-T12 and conventional 
inversion recovery technique. T2 values measured using ms-DSEPI-T12 were 
lower than those measured using TSE sequence, which may be due to the 
translation diffusion under background and imaging gradient (23). A 
simulation was performed to evaluate the error in T1 calculation propagated 
from the error in underestimated T2 using ms-DSEPI-T12. According to 
equation 3.6, 














ൌ ܵᇱ଴ሺݎറሻ · expሾെܶܧ଴ · ܴଶ · ܥሿ      . . . . ሺ3.6ሻ 
and the fact that T1 was calculated by curve fitting a series of ܵᇱ଴ሺݎറ|ݐሻ, the 
error in T1 was simulated with respect to different fractional error in T2  
estimation (Fig. 3.7a) and local concentration of the Gd-based contrast agent 
C (Fig. 3.7b), and using TE0 10 ms, T20 50 ms, and a spin-spin relaxivity R2 of 
10 L/mmol/sec. The same fractional error was used for both T20 and T2(C). For 
Fig. 3.7a, concentration C = 1 mmol/L, for Fig. 3.7b we assume 25% 
underestimation in both T20 and T2(C). 
Plots in Fig. 3.7 indicate that large fractional error in T2 estimate leads 
to much smaller fractional error in T1 calculation. Even for a high local 
contrast agent concentration C = 1 mmol/L, which can be hardly reached in 
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Figure 3.7. The computer simulation results of the fractional error in T1 changes 









normal applications, 25% fractional error in T2  induced less than 6% error on 
T1-maps. 
The signal recovery plots in Fig. 3.8 show the shortening of T1 values 
at a point in the tumor periphery indicated by the vertical arrow in Fig. 3.9 at 
three time points after administration of contrast agent. The imaging 
duration for each time point was 15.0 s, during which data were measured for 
three different saturation recovery times τi. 
The calculated T1, T2, and ΔR1 maps are displayed in Fig. 3.9 for a 
central slice, and their values are plotted vs. time in Fig. 3.10 at selected 9 
pixel regions of interest at the tumor periphery, the tumor core, and in 
muscle. No susceptibility induced distortion was noticeable on our dynamic 
T1 measurement MR images. T2 changes with contrast administration are 
negligible in this experiment, as presented in Figs. 3.9c and 3.10c. This is 
likely secondary to the low dose of 0.1 mM/kg of contrast agent used in this 
study.  Phantom studies suggest that the T2 shortening effect on the estimate 
of T1 may become significant at higher contrast concentrations, which might 
be encountered in dynamic tumor imaging. 
The dynamic change of ΔR1 maps in Fig. 3.9b was calculated using T1 
maps and equation 3.5. These ΔR1 images reflect the local distribution of the 
Gd[III] concentration. The temporal resolution using current technique may 
not be fast enough to accurately measure the arterial input function (AIF).  
The ΔR1 images can be used to calculate the model-based pharmacokinetic 
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 Figure 3.8. T1 recovery curve of a single pixel near the tumor periphery that is 








 Figure 3.9. Figures of a) T1 maps with T2 correction, b) ΔR1 maps, and c) T2 maps at 
precontrast, and 0.9, 5.1, and 9.9 min after the bolus administration of Gd-DTPA. 
The blue end of the color map indicates lower T1. Decreasing T1, i.e., increasing ΔR1, 
at the tumor periphery indicates increasing concentration of contrast agent. 




Figure 3.10. Plots of dynamic (a) T1, (b) ΔR1 and (c) T2 values of 3x3 pixel regions of 


















































































parameters, such as blood perfusion and tissue permeability using certain 
models like reference region model (24) and Brix model (25-26) that do not 
require AIF. Although further research and validation of these ΔR1 images 
are necessary for the absolute quantification, these ΔR1 images may be 
considered as the close representation to the contrast concentration. 
Phantom and in vivo studies show the accuracy and speed of the ms-
DSEPI-T12 technique for T1 and T2 mapping. This method is much faster 
than conventional inversion-recovery sequences for T1 mapping, and incurs 
little additional imaging time penalty for the addition of simultaneous T2 
mapping. Unlike the widely used technique of fast gradient echo imaging 
with flip angle variation, the T1 estimates obtained by our method are 
insensitive to B1 variation (20). 
The multishot echo planar technique allows flexible tradeoff between 
imaging time and susceptibility effects such as geometric distortion. Longer 
echo train lengths lead to decreased imaging time and resulting improvement 
in time resolution of T1 measurement, but also cause more severe artifacts 
from susceptibility. The increased echo trains may also result in 
underestimation of T2. 
The minimum recovery time is limited by the number of slices in 
current scheme, which may be erroneous to measure relatively short T1 such 
as 100 ms. One solution is to acquire short TR images in two interleaved 
acquisitions. The temporal resolution can be further improved by sliding 
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window technique, which regroups the data set for T1 map calculation. For 
instance, the data set with TRs [200, 500, 750], [200, 500,750] … can be 
grouped as [200, 500, 750], [500, 750, 200], [750, 200, 500], etc. 
3.4 Conclusions 
We have presented a rapid imaging method of simultaneous T1 and T2 
mapping which is suitable for high temporal resolution measurement of T1 
for dynamic contrast enhanced MRI. Unlike conventional gradient recalled 
echo sequences with variable flip angle, this sequence is insensitive to B1 
inhomogeneity. Our method allows simultaneous measurement of T2, which 
allows improved accuracy in T1 measurement by compensating for T2 effects. 
Accurate precontrast T1 measurement in association with dynamic T2 
measurement also allows more rapid post-contrast T1 measurement by 
reducing the number of saturation recovery time points necessary for 
accurate T1 recovery curve fitting.  Resulting T1 measurements agree 
experimentally with results obtained by slower inversion-recovery methods, 
with a fraction of the imaging time. Preliminary experiments in mice show 
that this method may be useful in dynamic contrast concentration MR 
imaging which may depict the distribution and pharmacokinetics of contrast 
agents or gadolinium-labeled pharmaceuticals. 
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OCULAR PHARMACOKINETICS STUDY OF A 
CORTICOSTEROID BY 19F MR 
 This chapter is based on the paper “Ocular pharmacokinetics study of 
a corticosteroid by 19F MR,” which was published on the journal 
Experimental Eye Research in 2010, authored by Xin Liu, S. Kevin Li and 
Eun-Kee Jeong. 
4.1 Introduction 
Corticosteroids such as triamcinolone acetonide (TA) and 
dexamethasone sodium phosphate (DSP) have been widely used in the 
treatment of macular edema and uveitis (1-2).  Intravitreal injection is an 
efficient way to deliver corticosteroid to the back of the eye to avoid systemic 
side effects. However, the intravitreal treatment is often short-lived, and 
repeated administration is usually required for chronic diseases (1). 
Information on how long the drug will stay in the eye after the initial 
injection and the clearance of the drug after the injection is of significance 
that can help healthcare practitioners understand the duration of the 
therapeutic effect and modify the dosing regimen for effective therapy.  
 
Conventional pharmacokinetics studies with animals require 
sacrificing the animals at different time points after drug administration, 
dissecting the eye, and analyzing different sections of the eye for the drug. 
The concentration of the drug in the eye tissues will then be determined 
using assays such as high-performance liquid chromatography (HPLC). 
However, this method is not applicable to humans. In human ocular 
pharmacokinetic studies, samples in the vitreous humor and anterior 
chamber could be extracted in conjunction with surgical procedures such as 
cataract surgery or vitrectomy (3-4), but the amount of the drug in the eye or 
in eye tissues cannot be measured accurately and can only be estimated. The 
lack of human pharmacokinetic data in ocular drug delivery research has 
hindered its development and the advance of ocular drug delivery 
technologies. A noninvasive approach to study ocular pharmacokinetics and 
drug clearance in the eye, e.g., after intravitreal injections, cannot only 
reduce the number of animals required in ocular drug delivery and 
pharmacokinetic research, but also allow the determination of the 
concentration profiles in the eye on a real time basis.  Such methods may also 
be applicable to humans in clinical studies.   
The objective of the present study was to develop a noninvasive way 
using 19F MR on a 3T clinical scanner to study ocular pharmacokinetics of 
fluorine containing therapeutic agents.  Particularly, the real time 
pharmacokinetics of intraocular triamcinolone acetonide phosphate (TAP) 
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was monitored after intravitreal injection. TAP is a prodrug of TA and has 
higher water solubility than TA (Fig. 4.1). The molecular weight of TAP is 
close to that of TA and DSP. Since the molecular structures of TAP and DSP 
are similar, the diffusion coefficient of TAP in the vitreous humor is expected 
to be similar to that of DSP, making TAP a useful surrogate to study the 
behavior of DSP clearance in the eye. 
4.2 Materials and Methods 
4.2.1 Materials 
TAP dipotassium salt was purchased from Crystal Pharma (Valladolid, 
Spain). TAP 0.09 M was prepared by dissolving TAP powder in deionized 
water. MnCl2 tetrahydrate was obtained from Spectrum Chemical (Gardena, 
CA). Ethylenediamine tetraacetic acid (EDTA) and xylazine were acquired 
from Sigma Chemical (St. Louis, MO). Na2MnEDTA solutions (0.02 M) were 
prepared by mixing MnCl2 with EDTA in deionized water and adjusting the 
pH of the solution to 7 with concentrated NaOH. 
4.2.2 Animals 
New Zealand white rabbits of 3 to 4 kg body-weight were purchased 
from Western Oregon Rabbit Co. (Philomath, OR). Animal experiments were 
conducted with the approval of the Institutional Animal Care and Use 
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4.2.3 Animal Experiments 
Rabbits were anesthetized by intramuscular injection of 25 to 50 mg/kg 
ketamine and 5 to 10 mg/kg xylazine.  The rabbits were then given either 
intravitreal or subconjunctival injections of 0.1 mL 0.09 M TAP mixed with 
approximately 1 µmol of Na2MnEDTA (MnEDTA ion). In postmortem rabbit 
studies, rabbits were sacrificed immediately before TAP injection. A total of 
12 eyes were used for intravitreal injection: 6 eyes of 3 rabbits in vivo and 6 
eyes of 3 rabbits postmortem; 6 eyes were used for subconjunctival injection: 
3 eyes of 2 rabbits (the other eye was used for other purposes, e.g., a control) 
in vivo and 3 eyes of 2 rabbits postmortem. 19F spectra were obtained at 
different time points after the injection. To determine the injection spot, 
MnEDTA ion was monitored with T1-weighted 1H imaging.  1H MRI was 
taken before and at the time points after the injections.  
4.2.4 MRI 
All MRI experiments were performed on a Siemens 3T Trio clinical 
imaging system (Siemens Medical Solution, Erlangen, Germany).  Because 
most of the clinical scanners do not have commercial 19F coils and coil-to-
scanner interface, a purpose-built circular linear surface coil with 1.5 inch 
diameter was tuned to 115.93 MHz to transmit the excitation pulse and 
receive the 19F NMR signal.  A similar coil with the same dimension was 
tuned to 123.22 MHz to acquire 1H anatomy images. The coil assembly 
consisted of an RF resonator, T/R switch, preamplifier, and the coil-plug. In 
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this experiment, surface coils were used to improve the signal detection 
sensitivity.  The 1.5 inch diameter coil allowed the rabbit eye to slightly 
protrude out of the coil plane, which made the eyeball sit symmetrically 
about the coil plane. This was to position the eyeball in the most sensitive 
region of the coil.  Since the surface coil field penetration depth was about 
same as the size as the coil, a coil diameter of 1.5 inches ensured that the 
sensitivity region of the coil covered deep enough for the eyeball. Active T/R 
switching with PIN diodes and a quarter-wave (λ/4) coaxial cable were used 
to switch between transmit and receive modes of the coil assembly. The same 
λ/4 was used for both proton and 19F channels.  A 3-200 MHz broadband 
preamplifier was used to amplify the received MR signals. A small vial of KF 
solution was attached to the 19F coil to generate a reference signal to 
calibrate the signal difference caused by coil loading variation.  
A dynamic 19F spectrum was obtained with a free induction decay (FID) 
pulse sequence: 1 s repetition time (TR), 0.15 ms receiver delay time, 16 kHz 
receiver bandwidth, 90° flip angle, 256 averages, and vector size of 1024. The 
data acquisition time was 4 min 20 sec. A rectangular (hard) RF pulse was 
used with a 200 μs pulse width.  The irradiation bandwidth (~10 kHz) 
covered both TAP and KF peaks (the two peaks were about 4-5 kHz apart on 
our 3T scanner). The NMR data were acquired at various time points after 
the intravitreal and subconjunctival injections as described in the “Animal 
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Experiment” section. For some rabbits, multiple measurements were taken at 
the same time points. 
High-resolution 1H images were acquired using a gradient recall echo 
(GRE) pulse sequence: field of view (FOV) 108 mm, 50% phase-FOV, spatial 
resolution 0.34×0.34×1.5 mm3, 20 slices, TR 400 ms, echo time (TE) 4.28 ms, 
400 Hz/pixel bandwidth, 2 averages, 60° flip angle, and acquisition time 2 
min 10 sec. 
The T1 of intravitreal TAP was also obtained during the experiment to 
determine if there was any T1 change with decrease of TAP concentration. 
FID pulse sequences were used to acquire T1 weighted spectra: 0.15 ms 
receiver delay time, 16 kHz bandwidth, 90° flip angle and 256 averages, 
repetition times were 200, 400, 800, 1600 and 3200 ms. 
4.2.5 MR Data Processing 
All 19F spectra were processed by custom-programmed MR 
spectroscopy analysis software developed using IDL (Interactive Data 
Language, ITT Visual Software, Boulder, CO). 10 Hz Gaussian apodization 
was applied in the time domain, followed by baseline correction, Fourier-
transformation, and phase-correction. The peak area integrations for both 
TAP and KF NMR lines were performed within the software. Ratios of the 
KF peak area to the TAP peak area at all time points were calculated then 
multiplied by TAP peak areas at each corresponding time point to create TAP 
signals with consistent coil sensitivity, i.e., normalized TAP signals. For each 
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rabbit eye, the relative TAP signals were calculated as ratios of the 
normalized TAP signals at different time points to the normalized TAP signal 
at the initial time point. 
4.3 Results 
4.3.1 Intravitreal and Subconjunctival Injections 
A typical 19F spectrum of TAP and KF obtained from our experiments 
is shown in Fig. 4.2a. The separation of two peaks is about 47 ppm, which is 
about 5.5 kHz on the 3T scanner. Fig. 4.2b shows the 19F spectra of a 
representative rabbit eye in vivo at different time points after intravitreal 
injection, where all spectra have been normalized to the KF spectrum. The 
data show the change in the spectrum over time throughout the experiment 
(from 0 to 22 hours). The TAP peaks maintained similar shapes and widths 
while the height decreased over time to the level of noise after 22 hours (the 
upper right spectrum). The signal-to-noise ratio (SNR) of the spectrum at the 
initial time point in the experiments ranges from 50 to 80. 
The 1H MR images of the same eye are shown in Fig. 4.3, immediately 
before, immediately after, and 5 hours after the intravitreal injection. The 
MR images of MnEDTA show the site of the injection.  The injection spot was 
close to the center of the vitreous body, and the solution immediately spread 
in both directions to the retina and the back of the lens.  The images also 
show that the shape of the injection spot in the vitreous was not entirely 




































































































































































































































Figure 4.3.  1H MR images (a) right before, (b) immediately and (c) 5 hours after the 





less resistive region behind the lens to the flow of the solution introduced by 
the needle during the injection.  At 5 hours after the injection, MnEDTA had 
spread throughout the vitreous body and other parts of the eye. In addition to 
showing the location of the intravitreal injection, the MnEDTA data also 
provided information on the diffusion pattern of TAP since MnEDTA and 
TAP have similar molecular weights (~386 and 529 Dalton, respectively) and 
are expected to have similar diffusion coefficients. 
Fig. 4.4 presents the amount of TAP at different time points after the 
intravitreal injection in vivo (6 eyes) and postmortem (6 eyes).  Fig. 4.5 shows 
the amount of TAP at different time points after the subconjunctival injection 
in vivo (3 eyes) and postmortem (3 eyes). The data of each eye were fit into a 
first order clearance model to determine the elimination half-life (t1/2) of the 
TAP signal in each experiment using the first order exponential function:  
ܣ ൌ ܣ଴ ൈ expሺെk୭ୠୱtሻ      . . . . ሺ4.1ሻ 
where A is the signal (proportional to the drug concentration), A0 is the initial 
signal, kobs is the rate constant, and t is time. The average elimination half-
life t1/2 was calculated and is presented in Table 4.1. 
4.3.2 19F T1 Measurement of Intraocular TAP 
The MR signal intensity follows an exponential recovery equation: 
ܵ ൌ ܵ଴ ൈ ሾ1 െ expሺെTR/Tଵሻሿ     . . . . ሺ4.2ሻ 
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 Figure 4.4. Relative TAP signal versus time after intravitreal injection in vivo and 
postmortem. The insert shows an enlarged view of the data. The line indicates the 
detection limit with the coil and pulse sequence used in this study. 
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 Figure 4.5. Relative TAP signal versus time after subconjunctival injection in vivo 
and postmortem.  The insert shows an enlarged view of the in vivo data. The line 




Table 4.1.  Summary of the first order rate constant and elimination half lifea. 
 kobs (h-1) t1/2 (h) 
Intravitreal injection in vivo 0.09±0.02 7.8±1.1 
Intravitreal injection postmortem 0.04±0.01 17.2±2.1 
Subconjunctival injection in vivo 1.4±0.2 0.5±0.1 
Subconjunctival injection postmortem 0.11±0.03 6.0±1.5 
a Mean±SD (n=3 for subconjunctival injection; n=6 for intravitreal injection).   
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where S and S0 are the transient and the equilibrium signal intensities, 
respectively. With a fixed TR, T1 change will affect the signal intensity. 19F T1 
was measured as 907±165 ms and 883±370 ms at 20 minutes and 4 hours 
after the intravitreal injection, respectively. The 19F T1 values of TAP were 
essentially the same that indicates negligible effect on the 19F signal intensity 
during the experiment. In the subconjunctival injection experiments, the TAP 
signal decayed quickly and T1 measurements were not performed. 
4.4 Discussion 
4.4.1 Ocular Clearance 
Drugs delivered through intravitreal injections can be eliminated 
through the aqueous humor outflow pathways in the anterior of the eye such 
as the canal of Schlemm or across the retinal/choroidal layer surrounding the 
vitreous (5-6).  For small molecules, the predominant route of clearance is 
suggested to be through the retina in the posterior segment of the eye (7).  
The diffusion of a drug in the vitreous mainly depends on its molecular 
weight (or molecular size), and permeation across the retina depends on the 
lipophilicity of the drug. Therefore, clearance from the vitreous, e.g., after 
intravitreal injections, generally depends on the molecular weight, 
lipophilicity, and charge of the molecule.  These factors also determine if 
clearance is diffusion or barrier controlled.  Small lipophilic molecules usually 
have faster clearance than charged molecules provided that binding to ocular 
tissues is not important.  For example, the terminal half-lives of small 
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molecules in the vitreous in rabbits can range from 3-4 h for the 
corticosteroid dexamethasone (8-9), to 5 h for the antibiotic carbenicillin (10) 
and to greater than 12 h for the antiviral foscarnet (11) that is used in the 
treatment of herpes and cytomegalovirus.  Whereas dexamethasone is 
lipophilic and uncharged having a molecular weight of 392 Daltons, 
carbenicillin and foscarnet are charged (2-, and 3-, respectively) with 
molecular weights of 378 and 126 Dalton, respectively. The half-life of third-
generation cephalosporins in the vitreous humor ranges from 5-20 h (12). In 
the present study, TAP, a charged molecule of 515 Dalton, had a half-life of 8 
h after intravitreal injection, which is consistent with the range provided in 
the literature. Clearance from the subconjunctival pocket and anterior 
chamber after subconjunctival injection is generally fast compared with that 
from the vitreous. In general, the half-lives of molecules in the 
subconjunctival pocket are approximately 0.3-0.5 h after subconjunctival 
injection(13-14).  Half-lives for clearance from the anterior chamber are less 
than 1 h for pilocarpine (15) and methazolamide (16) and up to 2 h for 
dorzolamide (17).  The TAP result after subconjunctival injection in the 
present study is in the same order of magnitude as those in the literature (18-
19). Clearance of intravitreal injection of drugs in suspension form is 
generally much slower than water soluble drugs.  Half-life of triamcinolone 
acetonide clearance from vitreous, for example, is 5-6 days (20). 
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TAP can be a surrogate to study ocular pharmacokinetics of 
therapeutic agents of similar physiochemical properties (molecular size and 
charge) and understand the mechanism of clearance after intravitreal and 
subconjunctival injections. For example, TAP and DSP have similar 
molecular weights, and if the clearance is diffusion controlled after 
intravitreal administration, the behavior of TAP clearance will be similar to 
that of DSP.   
4.4.2 Intravitreal and Subconjunctival Injections 
The present results show that the TAP signal decays at a much higher 
rate after subconjunctival injection in vivo than after intravitreal injection in 
vivo (1.4 vs. 0.09 h-1).  This is consistent with the mechanisms of ocular 
clearance and the pharmacokinetic profiles observed after subconjunctival 
and intravitreal injections in the literature (18-19).  A major difference 
between the routes of ocular clearance after subconjunctival injection versus 
intravitreal injection in vivo is the distance for TAP to reach the clearance 
site such as the blood vasculature in the choroid and retina or to reach the 
anterior chamber and the Schlemm’s canal.  Following subconjunctival 
injection, TAP is in direct contact with the blood vasculature in the 
surrounding tissues of the subconjunctival space.  Clearance of TAP after 
intravitreal injection requires diffusion across the vitreous humor before it 
can be cleared from the eye.   
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4.4.3 In Vivo and Postmortem Studies 
If euthanasia compromised the tissue barriers in the eye, an increase 
in TAP clearance was expected postmortem.  On the other hand, if clearance 
was the dominant factor, a decrease in TAP clearance was expected due to 
the lack of a functional vasculature around the eyes postmortem. The present 
data show significantly slower clearance of TAP from the eye in the 
postmortem animals compared with those in vivo: 0.04 vs. 0.09 h-1 for 
postmortem and in vivo after intravitreal injection, and 0.11 vs. 1.4 h-1 for 
postmortem and in vivo after subconjunctival injection, respectively.  This is 
consistent with blood circulation around the eyes being a dominant factor for 
the decrease in the TAP signal.  Although the blood retina barrier became 
compromised after animal death (21), an assumption that the tissues in the 
eye such as the choroid, retina, and endothelial cell tight junctions remained 
functionally and structurally intact postmortem (22) was made as a first 
approximation in the analysis.  Under this assumption, the effect of clearance 












where k1 is the rate constant of TAP clearance from the eye due to blood 
vasculature and other factors that cease at the death of the animal and k2 is 
the rate constant due to clearance such as passive diffusion and other factors 
in the animal postmortem.  Accordingly, k2 equals the rate constant of TAP 
observed postmortem and the sum k1+ k2 equals the apparent rate constant 
kobs of clearance in vivo.  A comparison of the in vivo and postmortem results 
shows that the rate constants k1 for TAP (e.g., blood vasculature clearance) 
are 0.05 and 1.3 h-1 after intravitreal and subconjunctival administrations, 
respectively. This corresponds to the termination half-life due to clearance of 
14 hr for intravitreal injection and 0.5 hr for subconjunctival injection. 
4.4.4 Other Considerations 
It has been suggested that the position of the intravitreal injection is 
important for drug distribution and elimination in the eye (23-24).  For 
example, when the site of injection for intravitreal delivery is at the center of 
the vitreous body and the TAP solution injected maintains a spherical shape, 
TAP would diffuse isotropically and then be cleared by blood vasculature at 
the retina. This scenario would result in the slowest clearance due to the 
diffusion that needs to take place.  However, as shown in Fig. 4.3 in the 
present study, MnEDTA had already reached the retina soon after the 
intravitreal injection. The problem is possibly caused by the relatively large 
amount of TAP solution (0.1 mL) injected, compared to the volume of the 
rabbit vitreous humor (0.7 ~ 1.5 mL). This would increase the clearance rate 
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of TAP after the injection and introduce variability in intravitreal injection in 
general.  
MnEDTA has been used in MRI and shows low toxicity at low 
concentration. In our experiments the concentration of MnEDTA solution 
injected is low. Therefore, it is unlikely that MnEDTA has retinal toxicity in 
our case and presence of MnEDTA would not affect the pharmacokinetics of 
TAP. 
Other factors that might contribute to the signal decrease include the 
degradation of TAP to TA in the eye, an inhomogeneous RF field distribution, 
and the change in T1 of TAP in different eye compartments or change of T1 by 
some factors, e.g., partial pressure of oxygen. The first explanation is based 
on the low solubility of TA in the vitreous humor; the aqueous solubility of TA 
is approximately 0.036 mg/mL (25) although a previous study has shown that 
the aqueous concentration of TA in the vitreous is 0.7 mg/mL (26) possibly 
due to TA interactions with the vitreous humor components. TA in solid state 
is expected to have a short T2 so the signal would decrease significantly when 
TAP is converted to TA and subsequently precipitated in the vitreous. 
However, this cannot explain the different results observed in the in vivo and 
postmortem experiments. The second explanation is related to coil signal 
inhomogeneity, in which TAP might diffuse to the places in the eye with less 
coil sensitivity. Again, if this were the major reason for the decrease in the 
TAP signal, the in vivo and postmortem experiments would not show 
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different results. The last explanation was found to be unlikely because T1 
measurements have shown similar T1 values (907 vs. 883 ms, respectively) at 
20 minutes and 4 hr after the injection. 
4.4.5 Detection and Limitations 
There are limitations using rabbits as an animal model to study 
pharmacokinetics at the back of the eye and extrapolate the results to human 
because the eyes such as the inner retinal blood circulations in rabbits and 
human are dissimilar. The goal of the present study is to eventual apply this 
technique on human in the future.  To use 19F MR to study ocular 
pharmacokinetics in human, some technical issues remain to be addressed. 
Particularly, the 19F MR method has relatively low sensitivity compared to 
traditional assay techniques (e.g., HPLC and GC).  The detection limit of 19F 
MR for TAP was about 0.18 µmol with the current RF coil and setup. When 
the TAP amount was less than 0.18 µmol in the eye, the signal was below 
noise level (about 2% of the 9 µmol initial total amount of the TAP injected). 
Although the SNR of the spectrum at the initial time points was 50-80 and 
provided sufficient detection in the present intravitreal and subconjunctival 
injection study, this detection limit may not be sensitive enough for ocular 
pharmacokinetic studies to evaluate other ocular drug delivery methods. 
Further hardware improvement or pulse sequence modification is required to 




A whole-body clinical MRI system was modified to perform 19F MR 
with a FID pulse sequence for noninvasive ocular pharmacokinetic studies. 
Ocular pharmacokinetic experiments were conducted using triamcinolone 
acetonide phosphate (TAP) as the model drug in rabbits in vivo and 
postmortem. The apparent elimination rate constants and half-lives of TAP 
in the eye after drug administration were determined. The difference in 
clearance observed in vivo and postmortem suggests the importance of fluid 
dynamics in the eye and blood circulation around the eyes to TAP clearance. 
The rate constants related to such clearance were then calculated.  The 
higher clearance after subconjunctival injection relative to that of intravitreal 
injection was believed to be due to the distance of the injection site from the 
blood vasculature. Finally, the present study demonstrates the feasibility of 
noninvasively monitoring the clearance of fluorine-containing drugs after 
ocular delivery using 19F MR, which may allow the eventual use of this 
method to study ocular pharmacokinetics in human. 
4.6 Acknowledgements 
This research was supported by NIH Grant EY15181. The authors 
thank Dr. Sarah A. Molokhia for her help in some experiments and Dr. Roy 




1. Kiernan DF, Mieler WF. The use of intraocular corticosteroids. Expert 
Opin Pharmacother 2009;10(15):2511-2525. 
2. Yilmaz T, Weaver CD, Gallagher MJ, et al. Intravitreal triamcinolone 
acetonide injection for treatment of refractory diabetic macular edema: 
a systematic review. Ophthalmology 2009;116(5):902-911; quiz 912-903. 
3. Cheng L, Banker AS, Martin M, Kozak I, Freeman WR. Triamcinolone 
acetonide concentration of aqueous humor after decanted 20-mg 
intravitreal injection. Ophthalmology 2009;116(7):1356-1359. 
4. Zaka-ur-Rab S, Mahmood S, Shukla M, Zakir SM, Khan BA, Owais M. 
Systemic absorption of triamcinolone acetonide after posterior sub-
Tenon injection. Am J Ophthalmol 2009;148(3):414-419. 
5. Maurice D. Review: practical issues in intravitreal drug delivery. J 
Ocul Pharmacol Ther 2001;17(4):393-401. 
6. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug 
delivery. Adv Drug Deliv Rev 2006;58(11):1131-1135. 
7. Worakul N, Robinson JR. Ocular pharmacokinetics/pharmacodynamics. 
Eur J Pharm Biopharm 1997;44:71-83. 
8. Graham RO, Peyman GA. Intravitreal injection of dexamethasone. 
Treatment of experimentally induced endophthalmitis. Arch 
Ophthalmol 1974;92(2):149-154. 
9. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and 
pharmacokinetics of dexamethasone after intravitreal injection. Arch 
Ophthalmol 1992;110(2):259-266. 
10. Barza M, Kane A, Baum J. The effects of infection and probenecid on 
the transport of carbenicillin from the rabbit vitreous humor. Invest 
Ophthalmol Vis Sci 1982;22(6):720-726. 
11. Berthe P, Baudouin C, Garraffo R, Hofmann P, Taburet AM, Lapalus P. 
Toxicologic and pharmacokinetic analysis of intravitreal injections of 
foscarnet, either alone or in combination with ganciclovir. Invest 
Ophthalmol Vis Sci 1994;35(3):1038-1045. 
12. Barza M, Lynch E, Baum JL. Pharmacokinetics of newer 
cephalosporins after subconjunctival and intravitreal injection in 
rabbits. Arch Ophthalmol 1993;111(1):121-125. 
91
13. Kim SH, Csaky KG, Wang NS, Lutz RJ. Drug elimination kinetics 
following subconjunctival injection using dynamic contrast-enhanced 
magnetic resonance imaging. Pharm Res 2008;25(3):512-520. 
14. Li SK, Molokhia SA, Jeong EK. Assessment of subconjunctival delivery 
with model ionic permeants and magnetic resonance imaging. Pharm 
Res 2004;21(12):2175-2184. 
15. Lee vHL, Robinson JR. Disposition of pilocarpine in the pigmented 
rabbit eye. Int J Pharm 1982;11:155-165. 
16. Maren TH, Jankowska L. Ocular pharmacology of sulfonamides: the 
cornea as barrier and depot. Curr Eye Res 1985;4(4):399-408. 
17. Sugrue MF. The preclinical pharmacology of dorzolamide 
hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul 
Pharmacol Ther 1996;12(3):363-376. 
18. Lee TW, Robinson JR. Drug delivery to the posterior segment of the 
eye II: development and validation of a simple pharmacokinetic model 
for subconjunctival injection. J Ocul Pharmacol Ther 2004;20(1):43-53. 
19. Lee TW, Robinson JR. Drug delivery to the posterior segment of the 
eye: some insights on the penetration pathways after subconjunctival 
injection. J Ocul Pharmacol Ther 2001;17(6):565-572. 
20. Oishi M, Maeda S, Hashida N, Ohguro N, Tano Y, Kurokawa N. 
Pharmacokinetic behavior of intravitreal triamcinolone acetonide 
prepared by a hospital pharmacy. Jpn J Ophthalmol 2008;52(6):489-
492. 
21. Berkowitz BA, Roberts R, Luan H, Peysakhov J, Mao X, Thomas KA. 
Dynamic contrast-enhanced MRI measurements of passive 
permeability through blood retinal barrier in diabetic rats. Invest 
Ophthalmol Vis Sci 2004;45(7):2391-2398. 
22. Kim H, Robinson MR, Lizak MJ, et al. Controlled drug release from an 
ocular implant: an evaluation using dynamic three-dimensional 
magnetic resonance imaging. Invest Ophthalmol Vis Sci 
2004;45(8):2722-2731. 
23. Friedrich S, Cheng YL, Saville B. Drug distribution in the vitreous 
humor of the human eye: the effects of intravitreal injection position 
and volume. Curr Eye Res 1997;16(7):663-669. 
92
24. Friedrich S, Cheng YL, Saville B. Finite element modeling of drug 
distribution in the vitreous humor of the rabbit eye. Ann Biomed Eng 
1997;25(2):303-314. 
25. Wiedmann TS, Bhatia R, Wattenberg LW. Drug solubilization in lung 
surfactant. J Control Release 2000;65(1-2):43-47. 
26. Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal sustained-
release triamcinolone and 5-fluorouracil codrug in the treatment of 






19F-MRI-BASED PHARMACOKINETICS ON A 3T 
CLINICAL MRI SYSTEM 
This chapter is based on the paper “19F-MRI-based pharmacokinetics 
on a 3T clinical MRI system,” which was submitted to the Journal of 
Magnetic Resonance Imaging in 2011, authored by Xin Liu, Zhong-Xing Jiang, 
Yihua Bruce Yu and Eun-Kee Jeong. 
5.1 Introduction 
    This traditional population pharmacokinetic (PK) study requires 
sacrificing a large number of animals at various time points. The organs are 
extracted, and the concentration of the drug in the organs is then determined 
in vitro, using assays such as high-performance liquid chromatography 
(HPLC). Such a PK study is based on the assumption that all the animals 
sacrificed at different time points have the same biological conditions. The 
degree to which this assumption is violated may introduce considerable 
variance in the PK parameters extracted from the data.  
    For in vivo experiments, only plasma or excreted drug concentration 
is normally accessible, but not tissue concentration. Plasma levels of 
compounds often differ from concentrations in specific tissues. The drug 
 
concentrations can be either higher or lower in the tissue compared to the 
plasma (1). 
MRI provides a noninvasive means to trace drug distribution in vivo. 
Dynamic-Contrast-Enhanced MRI (DCE MRI) with a paramagnetic contrast 
agent is commonly used to study pharmacokinetics (2-3). Paramagnetic ions 
can reduce the spin-lattice relaxation time (T1) of water proton NMR; as a 
result, T1-weighted images show enhanced signal intensities in the vicinity of 
paramagnetic ions. The higher the local concentration of paramagnetic ions, 
the larger the enhancement of the signal intensity. The signal intensity of 
NMR varies nonlinearly with the concentration of the contrast agent, 
according to the equations:                                 
















൅ ݎଶ ൈ ܥ     . . . . ሺ5.3ሻ 
Here, ܵሺܥሻ is the enhanced signal intensity, ܵ଴  is the thermal equilibrium 
signal intensity, TR is the recovery time, TE is the echo time, T1(C) and T2(C) 
are the concentration-dependent spin-lattice and spin-spin relaxation times, 
respectively, T10 is the spin-lattice relaxation time with no contrast agent, T20 
the spin-spin relaxation time with no contrast agent, C is the contrast agent 
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concentration, and r1 and r2 are the relaxivities of the contrast agent. At very 
low concentration, the signal intensity is approximately a linear function of 
the concentration of the contrast agent. Although the large concentration 
(about 88 M) of water protons provides great sensitivity for anatomical proton 
MR images, it also presents a potentially confounding and ubiquitous 
background signal in detecting the tracking agent, particularly if the latter is 
present at a much lower concentration. 
Nonproton MRI has rarely been used to study pharmacokinetics, 
because its signal intensity is generally low. Although hyperpolarized gas 
(3He or 129Xe) MRI can provide high signal intensity, and therefore high 
temporal resolution, the short life time (about 30 sec) of in vivo 
hyperpolarized gas limits the observation window. Also because the same 
flipangle is generally used at each time point, magnetization tipped to the 
transverse plane to generate the signal varies from one time point to another, 
making it hard to quantify tracer concentration over different time points. 19F 
MR has its advantages, although its signal intensity cannot be compared to 
hyperpolarized gas. It has a high gyromagnetic ratio compared to other non-
proton nuclei, no background signal, 100% abundance, and reusable 
magnetization (unlike hyperpolarized magnetization). 19F MR imaging and 
spectroscopy have been used to study a variety of biologic processes including 
metabolism (4-6), tumor growth (7-9), blood flow (10-11) and cell tracking 
(12). However, most fluorinated compounds are not for in vivo 19F MRI 
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applications because of their low-intensity signals, complex peak shapes that 
result in further signal loss, long T1, and long retention time in vivo due to 
low hydrophilicity or water solubility. 19F MR spectroscopy (MRS) has been 
used to investigate the clearance of the corticosteroid drug (triamcinolone 
acetonide phosphate) in the eye (13), delivery of psychiatric drugs, e.g., 
trifluorinated neuroleptics (fluphenazine and trifluoperazine) and 
trifluorinated antidepressants (fluoxetine and fluvoxamine) (14) and  
anticancer drugs, e.g., 5-FU (15-16). There are some 19F MR imaging studies 
on high field magnets (17-19) or using an extended acquisition time (20). In 
this paper, we present fluorine MR imaging with a newly developed fluorine 
compound, 19FIT (19F imaging tracer), which has 27 identical fluorine atoms 
with the same chemical shift, a relatively short T1, and high hydrophilicity 
(21).  
5.2 Materials and Methods 
5.2.1 Drug Preparations 
The 19FIT was efficiently synthesized in 11 synthetic steps on a scale of 
2-grams with a good yield (21-22). From commercially available starting 
material pentaerythritol and perfluoro-tert-butanol, the Mitsunobu reaction 
was employed as a key reaction to introduce 3 symmetrically-positioned 
trifluoro-tert-butyl groups. Then, 19FIT was synthesized in a sequential 
manner using repetitive deprotection/condensation cycles. Since most of the 
intermediates contain 27 fluorine atoms, those intermediates were easily 
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purified utilizing the unique separation power of fluorous chemistry. The 
final product 19FIT was purified using a combination of fluorous silica-gel 
chromatography and preparative HPLC.  Molecular weight and purity of the  
final product were verified by mass spectrometry and analytical HPLC, 
respectively. 
5.2.2 Animal Experiments 
BALB/C male white mice 60 - 80 days old were purchased from 
Charles River Laboratories International Inc. (Wilmington, MA). The animal 
experiment protocol was approved by the Institutional Animal Care and Use 
Committee at the University of Utah. Healthy mice were anesthetized by 
intramuscular injection of 100 mg/kg Ketamine and 5~10 mg/kg Xylazine. 
Two mice received 400 µl 150 mM 19FIT (2.2 mmol/kg 19FIT concentration, 60 
mmol/kg 19F concentration) and two mice received 200 µl saline and 200 µl 
150 mM 19FIT (1.1 mmol/kg 19FIT concentration, 30 mmol/kg 19F 
concentration) through the tail vein. During the MRI scan, the mice were 
placed on a mouse bed inside the imaging coil in a prone position. 19F images 
were obtained at different time points, and 1H images were acquired at the 
same location immediately after taking the 19F images. 
5.2.3 MRI Experiments 
All MRI experiments were performed on a clinical whole body 3T MRI 
system (Tim-Trio, Siemens Medical Solution, Erlangen, Germany) using a 
home-built 1H/19F dual-tuned volume coil with 2″ diameter and 3″ length  for 
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RF transmission and signal reception. A coil-to-system interface was 
constructed. Because the separation between two channels is only 7 MHz at 
3.0 T, the coil assembly consists of two separate channels. 19F and 1H 
channels of the coil were saddle-type coils, which are geometrically oriented 
at 90o to each other. The interface consists of a PIN-diode driven 
transmit/receive (T/R) switch, a broadband preamplifier (5 - 200 MHz), a coil-
selector switch with coil-code resistors, and a connector. The isolation 
between the receive and the transmit ports of the T/R switch was about -40 
dB when the PIN diode was driven.  
1H images were acquired using a 3D gradient echo (GRE) pulse 
sequence with 0.4×0.4×0.4 mm3 spatial resolution, 100×50 mm2 FOV, 7.73 ms 
TR, 2.74 ms TE, 25º flipangle, 150 Hz/pixel bandwidth, 2 averages and 1 min 
11 sec imaging time. 19F images were obtained at the same location by a 2D 
GRE pulse sequence with 1.5×1.5×3.0 mm3 spatial resolution, 192×96 mm2 
FOV, 400 ms TR, 2.98 ms TE, 90º flipangle, 260 Hz/pixel bandwidth, 16 
averages and 5 min 9 sec imaging time, 75 % asymmetric phase-encoding was 
used. All MR images were taken on the coronal plane. To assess the total 
fluorine amount, whole-body spectra were acquired using an FID pulse 
sequence with 8 averages, 100 kHz bandwidth, 0.15 ms TE and 1.6 sec TR. In 
vivo T1 of 19FIT was also measured using a series of whole body FID signals 
with recovery times of 0.2, 0.4, 0.8, 1.6, and 3.2 sec. 
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5.2.4 MR Data Processing 
All 19F spectra were processed using MR spectroscopy analysis 
software developed in our lab using IDL (Interactive Data Language, ITT 
Visual Software, Boulder, CO). The data were apodized with 10 Hz Gaussian 
line broadening, Fourier-transformed, and phase-corrected. The signal 
intensities of the whole-body FIDs were fit to an exponential recovery curve 
to extract T1. 
5.3 Results 
5.3.1 19F Spectra 
A typical fluorine spectrum obtained 2 days after the injection from one 
mouse, which received 2.2 mmol/kg 19FIT, is shown in Fig. 5.1.  There is no 
fluorine peak other than the one from 19FIT within 100kHz bandwidth. No 
other peak was observed at different time points or from different mice, 
which indicates that all fluorine nuclei in 19FIT have an identical chemical 
environment in vivo. MR spectroscopy and HPLC analysis were also done on 
the urine samples collected from the mice that received 19FIT. There was no 
sign of the degradation of 19FIT in vivo, as reported in our previous paper 
(21). The average of whole body fluorine FID signals were taken from two 
mice (which received 2.2 mmol/kg 19FIT) at a series of time points. The data 
points were fitted to the function S=S0+A×exp(-t/τ), and the elimination time 
constant τ was  calculated as 1030.0±55.3 min. For the two mice that received 
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 Figure 5.1. An in vivo whole body fluorine spectrum of one mouse which 
received 2.2 mmol/kg 19FIT, taken 2 days after the injection. 
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1.1 mmol/kg 19FIT, the elimination time constant τ is 1154.1±344.8 min, as we 
reported in our previous paper (21). 
After 2 days, whole-body signal intensities dropped down to one tenth 
from the initial signal intensity for both mice; 6 days later residual signals 
were 1/26 and 1/20 of the original amount for 2.2 mmol/kg and 1.1 mmol/kg 
doses, respectively. In other words, after 6 days, the total detectable 19F 
compounds were 0.085 mmol/kg and 0.055 mmol/kg for initial dosages of 2.2 
mmol/kg and 1.1 mmol/kg, respectively. 
5.3.2 Pharmacokinetics by 19F Imaging 
Fig.5.2 shows the 19F images of one mouse that received 2.2 mmol/kg of 
19FIT, at different time points and slices after the injection. Because of the 
lack of 19F background MR signal in vivo, the hyperintensities on the 19F 
images are derived only from the 19FIT signal. The SNR of these fluorine 
images at early time points around the heart and liver regions range from 5 
to 10. At later time points, when most of the 19FIT has accumulated in the 
bladder, the SNR around the bladder region is 30-40. 
For the mouse shown in Fig 5.2, at each time point, the fluorine signal 
in a given organ is obtained by summing over all the slices in that organ. The 
changes in the total fluorine signals over time from the different organs are 
plotted in Fig. 5.3a, the rapid fluorine signal drop in heart and liver, and 
dramatic increase in bladder signal during the first few hours can be 









































the 2.2 mmol/kg 19FIT dose and the two mice that received 1.1 mmol/kg 19FIT 
dose show a similar pattern and are plotted in Fig. 5.3b, c and d. The 
maximum concentration (Cmax) and area-under-curve (AUC) have been 
calculated using the organ fluorine signal curves, and are listed in Table 5.1. 
The T1 of the 19FIT solution in vial was 253.3±25.0 ms and in vivo T1 of 
19FIT from one mouse with 1.1 mmol/kg 19FIT was 393.1±48.0 ms, 368.2±5.9 
ms, 420.9±83.8 ms and 314.3±52.8 ms for times 0, 4 hours, 8 hours and 24 
hours after the injection. The prolonged T1 of 19FIT in vivo is possibly caused 
by the hindered molecular rotational motion of the compound in vivo and 
needs to be further investigated. 
To extract more information from specific organs, three regions of 
interest (ROI) were selected from the slice of the mouse shown in Fig. 5.2. 
The three ROIs are in the heart, liver and bladder, respectively. All the ROIs 
were chosen to have the same area. The mean value of the fluorine signals of 
each pixel inside the ROI was calculated for each time point. The time change 
curves are shown in Fig. 5.4. At the 2-hour time point, the signals from heart 
and liver ROIs are undetectable. Compared to the total organ signals shown 
in Fig. 5.3, the signal in the liver can still be detected at the 4-hour time 
point.  This indicates that different regions of the same organ (e.g., liver) 
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Table 5.1. M1, M2 indicate the two mice that received 2.2 mmol/kg 19FIT and 
M3, M4 indicate the two mice that received 1.1 mmol/kg 19FIT. The 19FIT 





 Cmax(a.u.) AUC (a.u.×hr)
Liver (M1) 41.8 62.4 




Liver (M2) 59.5 90.3 




Liver (M3) 17.9 10.1 




Liver (M4) 19.7 7.5 
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MRI is a powerful tool for studying drug distribution or metabolism in 
vivo in situ. 19F MRI of a fluorinated substance with a large number of 
chemically identical 19F nuclei has several advantages over a gadolinium-
based contrast agent, including the absence of background 19F NMR signal in 
biological tissue and direct observation of the imaging agent. The signal 
intensity of density-weighted 19F MRI is linear with the local concentration of 
the compound in the imaging voxel, unlike the nonlinear relationship 
between the 1H MRI signal intensity and the gadolinium-based contrast 
agent concentration. In this study, we tracked real time 19F pharmacokinetics 
quantitatively on a 3T clinical scanner with a reasonable time resolution (5 
min 9 sec). It is probable that this method could be used in human studies in 
the future because, unlike other methods, which use very long acquisition 
times that patients cannot tolerate, or high-field MRI systems (such as 7T or 
9.4 T) not currently available in clinics – it can be used on commonly-
available clinical scanners in reasonable imaging times. 
5.4.1 Pharmacokinetics Study of 19FIT 
The time curves for signal change in the various organs indicate the 
clearance pathway of intravenous 19FIT in mouse: 19FIT will go through heart 
and liver, then accumulate in the bladder and be excreted via urine (21). 
Because the 19F imaging resolution is considerably low, there is a partial 
volume effect when we calculate the signals from the heart and liver, 
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especially at some early time points when the signals in the liver and heart 
are connected together, as shown in Fig.5.2. 
The ROI signal curve can reveal more information about the compound 
dynamics inside each organ, to study the function of the organs. Since the 
mice were moved from one time point to another (except the first few points, 
which were obtained with the animal in the same position), there might be 
some misregistration problems for each ROI, although we tried to keep the 
mice in the same posture and position. 
Because of the linear relationship between fluorine signal and actual 
compound amount, fluorine signal change can be used to show the maximum 
uptake of the drug, which in some cases is information that can modify the 
therapy. Organ concentration can be used to extract PK parameters 
combined with plasma concentration using PK models. To obtain absolute 
quantification, we can put an external phantom with a known concentration 
of fluorine nuclei next to the subject and use the phantom signal as a 
reference to estimate the 19FIT level in vivo, as reported (23).  
From the in vivo 19F spectrum, since there is no other peak appearing 
within the 100 kHz bandwidth centered at the frequency of 19FIT, there is no 
breakdown of 19FIT in vivo or binding between 19FIT and tissue to affect the 
chemical shift of 19FIT. The whole body spectra can be used to monitor the 
total amount of 19FIT left inside the body, from which parameters such as 
elimination rate of the drug can be obtained.  
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5.4.2 Further Improvement of Fluorine Imaging 
Although the doses of 19FIT used in our experiments (1.1 and 2.2 
mmol/kg) are very high compared with clinical dose Gd-based contrast 
agents, e.g. 0.1 mmol/kg, no acute toxicity or weight loss was observed within 
45 days after the injection, as reported in our previous paper (21). The dose 
can be reduced by conjugating an increased number of fluorine atoms in each 
19FIT molecule. 
Currently the 19F imaging protocol is not optimized. Because of the 
relative long in vivo T1 (~300-400 ms) compared to TR, the 400 ms TR and 
90º flipangle make the fluorine imaging not only fluorine density weighted, 
but T1 dependent. This will make quantification more complicated. Since 
these are preliminary results, and the T1 of the compound can be shortened, 
which is discussed below, the results still show the feasibility of the dynamic 
fluorine imaging of 19FIT. 
One way to further improve SNR of 19F MRI is to add more fluorine 
atoms in each molecule.  The shortcoming is the higher hydrophobicity with 
more fluorine atoms which will increase the retention time of the compound. 
Another way is to reduce T1 of the compound. There are reports about using 
paramagnetic ion, e.g., Gd, to trim the relaxation times (T1 and T2) of the 
fluorine spin of fluorine compounds (24-25). With T1 shortened by nearby 
paramagnetic ions, the repetition time (TR) can be significantly reduced.  The 
reduced TR can either be used to shorten imaging times, or traded for an 
110
increase in the number of repetitions in the same time period, thereby 
increasing SNR.  
To increase the sensitivity of 19F imaging for human applications, it is 
possible to use a surface coil placed near the target organ. The drawback to 
this is very non-uniform sensitivity within the coil detection region, which 
leads to difficulties in quantification. 
5.5 Conclusions 
Whole-body dynamic fluorine imaging of a newly developed fluorine 
imaging agent, 19FIT, in mice is reported with fairly high spatial resolution 
and temporal resolution on a 3T clinical MRI scanner. The biodistribution 
and pharmacokinetics of 19FIT are obtained via 19F images for major uptake 
organs. The present study demonstrates the feasibility of using 19F MRI to 
investigate pharmacokinetics.  
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With novel development of more sophisticated and potent drugs, 
innovative drug delivery systems are required to insure the drug will release 
at the right time to the right target. It is beneficial to monitor the drug or 
imaging agent during the delivery process to evaluate the effectiveness of the 
drug delivery system. MRI provides a noninvasive method to quantitatively 
assess the in vivo pharmaceutical profile. 
Currently, MR imaging is conducted on 1H nuclei of the tissue water in 
clinical MRI, and imaging techniques are well developed and available on 
every clinical MR systems. Due to the large intrinsic 1H signal in living tissue, 
to utilize 1H MRI to monitor drug delivery, an imaging contrast agent as 
imaging tracer is required. GBCA has been widely used clinically as a T1 
relaxation contrast agent. It is necessary to measure the local concentration 
of GBCA for further quantification of the pharmacokinetics parameters, for 
instance, blood perfusion and tissue permeability calculation. To make the 
quantification of GBCA concentration rapid and accurate, a T1 and T2 
mapping technique ms-DSEPI-T12 was developed and shown in Chapter 3. 
 
ms-DSEPI-T12 greatly improved the temporal resolution of T1 mapping by 
utilizing the fact that the thermal magnetization of a pixel remains constant 
regardless of T1 shortening. For the current set up, each time point takes only 
15 seconds compared to several minutes using conventional imaging methods 
to measureT1, such as inversion recovery or saturation recovery. The 
accuracy of the technique was demonstrated via phantom experiments. The 
difference in T1 measurement using ms-DSEPI-T12 and inversion recovery is 
less than 1%. ms-DSEPI-T12 also shows superiority in insensitivity of B1 
variation to another rapid T1 mapping technique - fast gradient echo imaging 
with flipangle variation.  
Density-weighted 19F MR imaging and spectroscopy have advantages 
over 1H MRI for applications in quantitative drug delivery research, because 
of their linear relationship between the signal intensity and 19F concentration 
and no background signal interference. An application of 19F MR spectroscopy 
in ocular pharmacokinetics of corticosteroids is demonstrated in Chapter 4. 
The conventional methods to study ocular pharmacokinetics use the surgical 
procedure to extract tissue samples from the eye, and may cause severe 
complications and the drug concentration can only be estimated. Our study 
shows that 19F MR is a promising alternative approach that overcomes the 
major defects of conventional methods. 
Although 19F MR is proven beneficial in application to ocular 
pharmacokinetics, it also reveals one of the common weaknesses of MR 19F 
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imaging agent, the low signal intensity. Besides the low signal intensity, 
multiple chemical shifts, long T1 and long retention time of the 
perfluorocarbon (PFC) that are most commonly used for 19F MRI, prevent 
themselves from being suitable MR 19F imaging agents. Lack of desired 
imaging agents has hindered the applications of 19F MRI. A newly developed 
MR 19F imaging agent greatly overcomes these shortcomings, and the 19F 
MRI based pharmacokinetic study has been done in Chapter 5. Relatively 
higher SNR of the 19F dynamic images are obtained on a 3T clinical system.  
6.2 Limitations and Perspectives 
Current ms-DSEPI-T12 technique (temporal resolution 15 sec) is not 
fast enough to measure the arterial input function (AIF) to calculate 
pharmacokinetic parameters such as tissue permeability, which requires 
temporal resolution on one second order. To further boost the speed of the 
dynamic measurement, (1) a sliding window technique can be used, and (2) a 
larger echo train length might be helpful, although it induces increased 
geometric distortion due to variations in the local magnetic field because of 
the magnetic susceptibility. If the temporal resolution is still not high enough, 
then we have to adopt an AIF free model, e.g., reference region model. 
For 19F MR ocular pharmacokinetics project, DSP as a widely used 
corticosteroid in the treatment might be chosen as a role model in future 
studies. Because the clinical dosage of DSP is approximately 10 times less 
than that used in our TAP study, further improvement of the hardware is 
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required to increase the signal intensity. If the DSP sensitivity can exceed 
the detection limit, the technique might eventually be applied to humans. 
To improve the SNR or temporal resolution of 19FIT imaging, 
modifications to 19FIT can be done via (1) adding more fluorine atoms into the 
molecule, although it can reduce the hydrophilicity, and (2) utilizing a 
paramagnetic ion attached to 19FIT to reduce its T1 relaxation time. Besides, 
imaging sequence and sequence parameters can be more optimized.  
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